Subject Index

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abuse. See Physical and sexual abuse; Substance use disorders</td>
<td></td>
</tr>
<tr>
<td>Acalculias, 734</td>
<td></td>
</tr>
<tr>
<td>Acceptance and commitment therapy (ACT), 315, 384</td>
<td></td>
</tr>
<tr>
<td>Acculturation, 132–5</td>
<td></td>
</tr>
<tr>
<td>Actigraphy, 551–2, 553, 555, 557</td>
<td></td>
</tr>
<tr>
<td>Acute stress disorder (ASD): anxiety comorbidity with, 413</td>
<td></td>
</tr>
<tr>
<td>clinical features of, 412</td>
<td></td>
</tr>
<tr>
<td>description of, 409</td>
<td></td>
</tr>
<tr>
<td>diagnostic considerations for, 413</td>
<td></td>
</tr>
<tr>
<td>Age influences and differences: age cohort of ethnic minorities, 135, 136–7</td>
<td></td>
</tr>
<tr>
<td>in alcohol use, 674</td>
<td></td>
</tr>
<tr>
<td>in bipolar disorder, 211–12, 222–3</td>
<td></td>
</tr>
<tr>
<td>in depressive disorders, 8–10, 250, 259, 261–2, 266, 276–7, 738–9</td>
<td></td>
</tr>
<tr>
<td>in dissociative disorders, 454, 460</td>
<td></td>
</tr>
<tr>
<td>on dual diagnosis, 53–4</td>
<td></td>
</tr>
<tr>
<td>in feeding and eating disorders, 497, 498, 523</td>
<td></td>
</tr>
<tr>
<td>in gender dysphoria, 636–9, 643</td>
<td></td>
</tr>
<tr>
<td>in neurocognitive disorders, 731, 733, 738, 745, 750–1</td>
<td></td>
</tr>
<tr>
<td>in obsessive-compulsive disorders, 381–3</td>
<td></td>
</tr>
<tr>
<td>in personality disorders, 770</td>
<td></td>
</tr>
<tr>
<td>in physical illnesses, 67</td>
<td></td>
</tr>
<tr>
<td>in schizophrenia, 182–3</td>
<td></td>
</tr>
<tr>
<td>in sexual dysfunctions and paraphilic disorders, 578–81, 584, 588, 599–600</td>
<td></td>
</tr>
<tr>
<td>in sleep disorders, 550, 554, 558, 560, 561</td>
<td></td>
</tr>
<tr>
<td>on structured and semistructured interviews, 111</td>
<td></td>
</tr>
<tr>
<td>in substance use disorders: alcohol, 53–4, 674</td>
<td></td>
</tr>
<tr>
<td>in substance use disorders: drugs, 53–4, 695, 696, 704</td>
<td></td>
</tr>
<tr>
<td>Agnosias or gnostic disorders, 727, 735</td>
<td></td>
</tr>
<tr>
<td>Agoraphobia. See also Anxiety disorders description of, 306</td>
<td></td>
</tr>
<tr>
<td>dual diagnosis including, 56</td>
<td></td>
</tr>
<tr>
<td>panic disorders with, 300–1, 306, 317</td>
<td></td>
</tr>
<tr>
<td>personality and temperament in, 322</td>
<td></td>
</tr>
<tr>
<td>structured and semistructured interviews on, 115</td>
<td></td>
</tr>
<tr>
<td>substance use comorbidity with, 56</td>
<td></td>
</tr>
<tr>
<td>Agraphias, 734</td>
<td></td>
</tr>
<tr>
<td>AIDS. See HIV and AIDS</td>
<td></td>
</tr>
<tr>
<td>Alcoholics Anonymous, 670</td>
<td></td>
</tr>
<tr>
<td>Alexias, 734, 735</td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s disease, 727, 732, 738, 739, 740, 745–6, 749, 750</td>
<td></td>
</tr>
<tr>
<td>Amenorrhea, 498</td>
<td></td>
</tr>
<tr>
<td>American Academy of Pediatrics (AAP), 523</td>
<td></td>
</tr>
<tr>
<td>American Academy of Sleep Medicine, 549</td>
<td></td>
</tr>
</tbody>
</table>
American Psychiatric Association (APA):  
DSM by (see Diagnostic and Statistical Manual of Mental Disorders)  
eating disorder treatment guidelines, 523  
American Psychological Association, 672  
Amnesia:  
alcoholic Korsakoff’s syndrome as, 737–8, 747, 749  
anterograde vs. retrograde, 737  
dissociative amnesia as, 451, 452, 453, 454–5, 456, 463, 476  
as neurocognitive disorders, 736–8, 747, 749, 751  
post-traumatic, 751  
temporal lobe amnesia as, 738  
Amok, as culture-bound syndrome, 456  
Amplitude from electroencephalogram (EEG), 39  
Androgen deficiency in the aging male (ADAM), 586  
Aneurysms, 744, 745, 751  
Anger and hostility. See also Conduct or disruptive behavior disorders; Violence  
dissociative disorder comorbidity with, 467  
heritability of, 768  
personality disorder comorbidity with, 768, 769  
schizophrenia comorbidity with, 163  
Animal fears:  
racial, ethnic and cultural factors impacting, 139  
specific phobias as, 303, 308, 318, 330  
Anorexia nervosa (AN):  
atypical, 499  
clinical picture of, 497–8  
cognitive functioning with, 518–20  
course and prognosis of, 522–3  
description of, 497  
diagnostic considerations for, 499–500  
dual diagnosis including, 56  
epidemiology of, 501  
etiological considerations for, 506, 507, 508, 509  
genetic risk factors for, 507  
neuropathological function with, 510–11, 512–13  
psychological and biological assessments of, 502–3  
racial, ethnic and cultural factors in, 139, 140, 521–2  
substance use comorbidity with, 56  
treatments and interventions for, 523  
Antisocial personality disorders:  
case study of, 777–80  
clinical picture of, 766  
common factors model on, 75  
dimensional vs. categorical classification of, 15  
dual diagnosis including, 48  
epidemiology of, 768  
etiological considerations for, 768  
gender dysphoria comorbidity with, 640  
psychological assessments of, 775  
structured and semistructured interviews on, 118  
substance use comorbidity with, 48, 673, 711  
Anxiety disorders. See also Trauma- and stress-related disorders  
acceptance and commitment therapy for, 315  
agoraphobia, 56, 115, 300–1, 306, 310, 311, 312, 313, 315, 317, 318, 319, 322, 329  
behavioral assessments/consideration with, 310–11, 323–4  
bidirectional model on, 82  
bipolar disorder comorbidity with, 223  
classical conditioning of, 323  
cognitive-behavioral therapy for, 313–14  
cognitive functioning with, 324–7  
combined treatments for, 316–17  
costs of, 299  
course and prognosis of, 306, 307, 308, 309, 328  
depression comorbidity with, 6, 259, 307, 319  
description of, 299–305  
diagnostic considerations for, 304–5  
dimensional vs. categorical classification of, 4, 5, 6, 13, 14, 15, 304  
dual diagnosis including, 50–9, 63, 66, 69, 70, 71, 82, 83  
environmental risk factors for, 327–8  
epidemiology of, 305–9  
etiological considerations for, 318–20  
exposure therapy for, 314  
eye movement desensitization and reprocessing for, 315  
feeding and eating disorders comorbidity with, 500, 523  
gambling disorder comorbidity with, 53–4  
gender dysphoria comorbidity with, 640
gender influences and differences in, 306, 307, 308
generalized, 57, 136, 259, 301–2, 306–7, 312, 313–14, 320–1, 364, 554
genetic risk factors for, 318, 321
informational acquisition in, 324
interpersonal therapy for, 315–16
life functioning with, 304
meditation for, 315
mindfulness approaches for, 315
neurobiological function in, 320–1
obsessive-compulsive (see Obsessive-compulsive anxiety disorders)
oprant conditioning of, 323–4
overview of, 299
panic disorder as, 48, 57, 59, 71, 115, 299–300, 305–6, 312, 313, 320, 562
performance, 582, 583, 584, 586, 587, 591
personality and temperament in, 322–3
pharmacologic interventions for, 312–13, 316–17
preparedness theory on, 324
psychoanalytic psychotherapy for, 315
psychological assessment of, 309–12
racial, ethnic and cultural factors in, 131, 132, 134, 136, 137–8, 140–1, 142, 145, 303, 328–9
schizophrenia comorbidity with, 162
self-monitoring of, 311
self-report measures for, 310, 311, 314
separation, 364
sexual dysfunctions and paraphilic disorders comorbidity with,
Binge-eating disorder (BED) (Continued)
dual diagnosis including, 56
environmental risk factors for, 517, 518, 526
epidemiology of, 501
etiological considerations for, 506, 509–10, 512, 513, 515, 518–19, 520
genetic risk factors for, 509–10
neurobiological function with, 512, 513
psychological and biological assessments of, 503, 505
racial, ethnic and cultural factors in, 521–2
substance use comorbidity with, 56
treatments and interventions for, 524
Biological assessments:
for anxiety disorders, 318–20
for depressive disorders, 265
for feeding and eating disorders, 504–5
for gender dysphoria, 644
for neurocognitive disorders, 740–1
for schizophrenia, 173
for sexual dysfunctions and paraphilic disorders, 582–3, 606–7
for somatic symptom and related disorders, 436–7
for substance use disorders: alcohol, 675–80
for substance use disorders: drugs, 703–4
for trauma- and stress-related disorders, 414
Biotypes, 39
Bipolar disorder:
age influences and differences in, 211–12, 222–3
anxiety comorbidity with, 223
attention deficit/hyperactivity disorder relationship to, 221
bipolar spectrum, 220–1
brain regions involved in, 227–9
case study of, 229–30
child and adolescent diagnosis of, 222–3
clinical picture of, 212–14
ego-behavioral therapy for, 218
ego functioning with, 61, 62, 215–16
course and prognosis of, 214–20
description of, 209–11
diagnostic assessment methods for, 224
diagnostic considerations for, 220–4
dimensional vs. categorical classification of, 4, 6
dual diagnosis including, 48, 52, 53, 55–6, 57, 58, 60, 61–2, 64–5, 66, 70, 75, 77, 223–4
eating disorder comorbidity with, 57
evironmental risk factors for, 214–15
epidemiology of, 211–12
etiological considerations for, 225–7
family-focused therapy for, 219, 220
future study of, 230–1
genre dysphoria comorbidity with, 640
genre influences and differences in, 212
genetic risk factors for, 75, 225, 226
goal dysregulation in, 216–17
interpersonal and social rhythm therapy for, 219–20
life functioning with, 213–14
medical comorbidity and mortality, 214
neurobiological function in, 226–7
overview of, 209, 230–1
pharmacologic interventions for, 65, 212, 218, 227
psychoeducation for, 218–20
racial, ethnic and cultural factors in, 134, 212
schizophrenia comorbidity with, 166
service utilization with, 65
sleep disorder comorbidity with, 217
structured and semi-structured interviews on, 224
substance use comorbidity with, 52–3, 55–6, 58, 60, 64, 65, 66, 70, 77, 223
subtypes of, 212
suicide/suicide ideation comorbidity with, 65, 213, 215, 227
symptom overlap with, 70, 166–7, 640
Systematic Treatment Enhancement Program for Bipolar Disorder, 212, 220, 230
trauma- and stress-related disorder comorbidity with, 223
treatments and interventions for, 65, 212, 217–20, 227
Blood analysis, 703–4
Body dysmorphic disorder (BDD):
case study of, 386–7
clinical features of, 362
cognitive functioning with, 377
course and prognosis of, 382–3
description of, 359–60
diagnostic considerations for, 364
dimensional vs. categorical classification of, 6
environmental risk factors for, 374–5
epidemiology of, 365
etiological considerations
gender influences and
differences in, 380
genetic risk factors for, 369
neurobiological function
with, 371–2
as obsessive-compulsive
related disorder, 359–60, 362, 364, 365, 367, 369, 386–7, 640
psychological and
biological assessments
of, 367
racial, ethnic and cultural
factors in, 380
suicide/suicide ideation
comorbidity with, 362, 382
symptom overlap with, 640
treatments and
interventions for, 386–7
Borderline personality
disorders:
case study of, 777–80
clinical picture of, 766, 767
common factors model on,
75
course and prognosis of,
771
depressive disorder
comorbidity with, 247, 259
dialectical behavior therapy
for, 771
dimensional vs. categorical
classification of, 15
dissociative disorder
comorbidity with, 458
dual diagnosis including,
52, 57, 59
epidemiology of, 768
etiological considerations
for, 768, 770
gender dysphoria
comorbidity with, 640
mentalization-based
therapy for, 771
personality dynamics in,
760
pharmacologic
interventions for, 771
psychological assessments
of, 775
schema-focused therapy
for, 771
separation of personality
pathology and, 763
substance use comorbidity
with, 52, 56, 59, 75, 673, 698, 611
symptom overlap with,
457, 640
transference-focused
therapy for, 771
treatments and
interventions for, 771
Brain function. See Cognitive
functioning;
Neurobiological
function
Breath analyzer, 680
Breathing-related sleep
disorders, 549, 553, 562
Brief cognitive-behavioral
therapy, 419
Broca’s aphasia, 728, 729, 734
Bulimia nervosa (BN):
clinical picture of, 498–500
cognitive functioning with,
518, 519
description of, 497
diagnostic considerations
for, 500
dual diagnosis including,
56, 57
environmental risk factors
for, 515
epidemiology of, 501
etiological considerations
for, 506, 509, 510, 511, 513, 514
genetic risk factors for, 509
neurobiological function
with, 510, 511, 513
psychological and
biological assessments
of, 502–3, 504
racial, ethnic and cultural
factors in, 521
substance use comorbidity
with, 56, 57
treatments and
interventions for, 524
Case study:
of bipolar disorder, 229–30
of depressive disorders,
282–4
of dissociative disorders,
466–7
of feeding and eating
disorders, 524–6
of gender and eating
disorders, 655–6
of obsessive-compulsive
disorders, 385–6
of personality disorders,
777–80
of schizophrenia, 184–6
of sexual dysfunctions and
paraphilic disorders,
595–6, 612–13
of sleep disorders, 563–4
of somatic symptom and
related disorders, 441–3
of substance use disorders:
alcohol, 685–7
of substance use disorders:
drugs, 712–13
of trauma- and stress-
related disorders, 420
Catatonia, 249, 253
Centers for Disease Control,
498
Child abuse. See Physical and
sexual abuse
Chinese Classification of
Mental Disorders, 138
Chronic fatigue syndrome,
139
Circadian rhythm sleep-wake
disorders, 549, 552, 553, 556–8
Clinical considerations:
bipolar disorder,
case study, 212–14
case study of bipolar disorder,
229–30
case study of depressive disorders,
282–4
case study of dissociative disorders,
466–7
case study of feeding and eating
disorders, 524–6
case study of gender and eating
disorders, 655–6
case study of obsessive-compulsive
disorders, 385–6
case study of personality disorders,
777–80
case study of schizophrenia, 184–6
of sexual dysfunctions and
paraphilic disorders,
595–6, 612–13
case study of sleep disorders, 563–4
case study of somatic symptom and
related disorders, 441–3
of substance use disorders:
alcohol, 685–7
of substance use disorders:
drugs, 712–13
of trauma- and stress-
related disorders, 420
of depressive disorders,
282–4
of dissociative disorders,
466–7
of feeding and eating
disorders, 524–6
of gender and eating
disorders, 655–6
of obsessive-compulsive
disorders, 385–6
of personality disorders,
777–80
of schizophrenia, 184–6
of sexual dysfunctions and
paraphilic disorders,
595–6, 612–13
of sleep disorders, 563–4
of somatic symptom and
related disorders, 441–3
of substance use disorders:
alcohol, 685–7
of substance use disorders:
drugs, 712–13
of trauma- and stress-
related disorders, 420
of depressive disorders,
282–4
of dissociative disorders,
466–7
of feeding and eating
disorders, 524–6
of gender and eating
disorders, 655–6
of obsessive-compulsive
disorders, 385–6
of personality disorders,
777–80
of schizophrenia, 184–6
of sexual dysfunctions and
paraphilic disorders,
595–6, 612–13
of sleep disorders, 563–4
of somatic symptom and
related disorders, 441–3
of substance use disorders:
alcohol, 685–7
of substance use disorders:
drugs, 712–13
of trauma- and stress-
related disorders, 420

Subject Index 851
Clinical considerations

(Continued)
clinical utility of diagnosis, 108, 110, 118, 757–8, 777
depressive disorders, clinical picture of, 254–6
feeding and eating disorders, clinical picture of, 497–9
gender dysphoria, clinical picture of, 635–9
neurocognitive disorder clinical presentation, 727–33
obsessive-compulsive disorders, clinical features of, 360–3
personality disorders, clinical picture of, 766–7
schizophrenia, clinical picture of, 160–4
sexual dysfunctions and paraphilic disorders, clinical picture of, 574–7, 597–603
somatic symptom and related disorders, clinical picture of, 430–3
substance use disorders: alcohol, clinical picture of, 671–2
trauma- and stress-related disorders, clinical features of, 411–12

Cognitive-behavioral therapy (CBT):
for anxiety disorders, 313–14
for bipolar disorder, 218
brief CBT as, 419
for dissociative disorders, 467, 478
for feeding and eating disorders, 524
for obsessive-compulsive disorders, 382–4
for sexual dysfunctions and paraphilic disorders, 589, 591, 593, 611, 613

for somatic symptom and related disorders, 440
for trauma- and stress-related disorders, 418–19

Cognitive functioning. See also Neurobiological function
anxiety disorders and, 324–7
bipolar disorder impacting, 61, 62, 215–16
depressive disorders impacting, 254–5, 271
dissociative disorders and, 474–6
dual diagnosis relationship to, 61–3, 75, 79
feeding and eating disorders and, 518–21
gender dysphoria and, 653–5
neurocognitive disorders impacting, 725–52
obsessive-compulsive disorders and, 376–9
personality disorders and, 769–70
psychoses and, 63
schizophrenia impacting, 60, 61, 160, 161, 170, 178, 182
sexual dysfunctions and paraphilic disorders and, 611
somatic symptom and related disorders and, 439
substance use disorders: alcohol and, 60, 61, 678, 681, 683, 686
substance use disorders: drugs and, 60, 61, 706–9
trauma- and stress-related disorders and, 414, 418
Cognitive Processing Therapy (CPT), 417, 418
Cognitive restructuring:
for anxiety disorders, 314
Cognitive Processing Therapy (CPT) as, 417, 418

for dissociative disorders, 467
for obsessive-compulsive disorders, 382, 389
for trauma- and stress-related disorders, 418
Coital alignment technique (CAT), 589
Collaborative Longitudinal Personality Disorders Study, 122, 770
Common factors model, 75–6
Community functioning, schizophrenia impacting, 172
Community Tracking Study, 66

Comorbidity:
of anxiety disorders, 50–9, 63, 66, 69, 70, 71, 82, 83, 259, 304–5, 306–9, 312, 317, 364, 413, 435, 440, 500, 523, 549, 552, 553, 554, 558, 564, 582, 583, 584, 586, 587, 591, 640, 673, 678, 698, 699, 709
of attention deficit/hyperactivity disorder, 223–4, 364
of bipolar disorder, 48, 52, 53, 55–6, 57, 58, 60, 61–2, 64–5, 66, 70, 75, 77, 166, 212, 214, 215, 223–4, 227, 640
complexity of, 50, 54–5, 74, 82, 83
of conduct or disruptive behavior disorders, 74, 75
co-occurrence vs., 6
dimensional vs. categorical classification, 6

Cognitive functioning. See also Neurobiological function
anxiety disorders and, 324–7
gender dysphoria and, 653–5
neurocognitive disorders impacting, 725–52
obsessive-compulsive disorders and, 376–9
personality disorders and, 769–70
psychoses and, 63
Cognitive-behavioral therapy (CBT): for anxiety disorders, 313–14
Cognitive Processing Therapy (CPT): for anxiety disorders, 313–14
of dissociative disorders, 457, 459, 472, 640
dual diagnosis of, 45–84, 223–4, 259, 433–4, 460–2
of feeding and eating disorders, 56, 57, 460, 500, 517, 523, 526, 709
of gambling disorders, 47–8, 51
of gender dysphoria, 602, 604, 635, 638, 640–2, 643–4, 645
of impulse-control disorders, 364
of neurocognitive disorders, 725, 733–9, 742
of obsessive compulsive disorders, 48, 52, 56, 59, 71, 259, 362, 363–4, 378, 380, 382, 384
of personality disorders, 48, 52, 54–7, 58–9, 60, 70, 247, 259, 364, 413, 457, 459, 435, 440, 500, 640, 673, 698–9, 760, 761, 762, 778
of physical illnesses, 440, 500, 523–4, 549, 552, 553, 554, 555–6, 557–8, 559, 560–1, 562, 573, 577, 579, 582, 583–4
of psychoses, 640, 643
of schizoaffective disorder, 460
of schizophrenia, 46, 46, 48, 49, 52, 53, 55, 57, 60–5, 68–9, 70, 71, 75, 77–80, 81–2, 164–8, 259, 460, 640, 698
of sexual dysfunctions and paraphilic disorders, 460, 573, 579, 584, 586, 588, 635
of sleep disorders, 217, 410, 460, 476–7, 459, 551, 554, 555–6, 557, 561, 562
of somatic symptom and related disorders, 254, 433–4, 435, 440
of somatic symptom and related disorders, 217, 410, 460, 476–7, 459, 551, 554, 555–6, 557, 561, 562
of substance use disorders: substance use impacting, 75
Cross-dressing. See Transvestic disorder
Culture. See Racial, ethnic and cultural factors
Cyberball, 783
Cyclothymia, 221, 230. See also Bipolar disorder
delirium, 726–7, 730, 747
Delusional disorder, 167–8
Dependent personality disorders:
classification of, 458
differential diagnosis of, 458
etiological considerations for, 768
Depersonalization/
derealization disorder (DDD):
cognitive-behavioral therapy for, 478
description of, 451, 457
diagnostic considerations for, 457
epidemiology of, 458
psychological assessments of, 462, 463
treatments and interventions for, 477
Depressive disorders. See also Bipolar disorder
age influences and differences in, 7–8, 53–4, 250, 259, 261–2, 266, 276–7, 738–9
anxiety comorbidity with, 6, 259, 307, 312
case studies of, 282–4
catatonia with, 249, 253
clinical picture of, 254–6
cognitive functioning impacted by, 254, 271
continuum of depression, 7, 8–10
costs associated with, 256
course and prognosis of, 279–80
Depressive disorders. See also Bipolar disorder
(Continued)
depression not as a disorder, 253–4
depressive disorder due to another medical condition, 251–2
depressive personality disorder as, 7–8
description of, 248–54
diagnostic considerations for, 256–9
diagnostic specifiers for, 262–3
dimensional vs. categorical classification of, 4, 5, 7–11
dissociative disorder comorbidity with, 460
dual diagnosis including, 46, 48, 50, 52, 54, 55–7, 58–61, 65, 66, 69, 70, 72, 75, 77, 79, 80–1, 259
eye early onset dysthymia as, 7–8, 250
environmental risk factors for, 252, 263–4, 276–7
epidemiology of, 259–64
etiological considerations for, 268–78
feeding and eating disorders comorbidity with, 500, 523
gambling disorder comorbidity with, 54
gender dysphoria comorbidity with, 635, 640
gender influences and differences in, 261, 277–8
 genetic risk factors for, 75, 269–70, 318
grief and bereavement relationship to, 10–11, 256, 258
life functioning with, 255
major depressive disorder, 247, 249, 282
neurasthenia similarity to, 139
neurobiological function in, 270–3, 728–9
obsessive-compulsive disorder comorbidity with, 364
other specified or unspecified depressive disorders, 248, 252, 283–4
peripartum depressive disorder, 253
persistent depressive disorder, 248, 250, 268, 279, 280
personality disorder comorbidity with, 247, 259, 279
pharmacologic interventions for, 10
physical illness relationship to, 251–2, 256–7
positive psychology for, 255
premenstrual dysphoric disorders, 248, 250
pseudodementia as late life depression, 738–9
psychological and biological assessment of, 264–8
psychotic features of, 253
racial, ethnic and cultural factors in, 133, 134, 135, 136–7, 141, 142, 148, 258, 262–3, 278
schizoaffective disorder relationship to, 167–8
schizophrenia comorbidity with, 161, 166–7, 259
screening instruments for, 264–8
secondary psychiatric disorder models on, 80–1
self-medication for, 77
service utilization with, 65–7
sexual dysfunction and paraphilic disorder comorbidity with, 573, 579, 584, 586, 588
sleep disorder comorbidity with, 551, 554, 555–6, 557, 561, 562
social functioning impacted by, 255
somatic symptom comorbidity with, 254, 256, 435, 440
special settings impacting, 263–4
structured and semistructured interviews on, 111, 115, 118, 119, 121, 124, 264, 267–8
substance/medication induced depressive disorder, 70–2, 80–1, 248, 250–1, 258
substance use comorbidity with: drugs, 46, 48, 50, 52, 54, 55–7, 58–61, 65, 66, 69, 70, 72, 75, 77, 79, 80–1, 247, 257–9, 698, 713
subthreshold major depression, 10–11
suicide/suicide ideation comorbidity with, 65, 247
symptom overlap with, 70, 166, 304–5, 318, 457, 738–9
taxometric analyses of, 9–10
trauma- and stress-related disorder comorbidity with, 413
treatments and interventions for, 10, 65–7, 247, 255–6, 280–1
Detachment, RDoC and, 783–4
Diabetes, 83, 256, 257, 264, 265, 267, 273, 274, 505, 524, 554, 556, 583, 584, 587, 588, 712, 744, 750
Diagnosis and assessment. See also specific topics below for additional detail
age influences and differences in, 111
anxiety disorders
diagnostic considerations, 304–5
assessment tools for (see Diagnostic and assessment tools)
behavioral assessments, 310–11, 365–6
bipolar disorder diagnostic considerations, 220–4
clinical training in, 107
clinical utility of, 108, 110, 118, 759–60, 777
depressive disorders diagnostic considerations and specifiers, 252–3, 256–9
diagnostic boundaries, 5–19
dimensional vs. categorical classification in, 3–22, 304, 777
dissociative disorders diagnostic considerations, 455–6, 458–60
dual, 45–84, 223–4, 259, 433–4, 640–2 (see also Comorbidity)
dual disorders impacting, 70–2, 72–4, 433–4
factor pattern investigations for, 137
family assessments, 172–3
feeding and eating disorders diagnostic considerations, 499–500
gender dysphoria diagnostic considerations, 639–42
item response theory (IRT) methodology of, 12–13
neurocognitive disorder diagnostic considerations, 726–7
obsessive-compulsive disorder diagnostic considerations, 364
personality disorder diagnostic considerations, 764–6
psychopathology research reliance on, 72–4, 113
rational, ethnic and cultural factors impacting, 131–2, 133, 137–143, 263
reference tools for (see Diagnostic and Statistical Manual of Mental Disorders; International Classification of Diseases)
reliability of, 106, 108–9, 127
Research Domain Criteria (RDoC) for, 21
schizophrenia diagnostic considerations, 164–8
sexual dysfunction and paraphilic disorder diagnostic considerations, 578, 603–4
sleep disorder diagnostic considerations, 553–4, 555, 557, 559, 560, 562, 563
somatic symptom and related disorders diagnostic considerations, 433–4
substance use disorder: alcohol, diagnostic considerations, 672–4
substance use disorder: drugs, diagnostic considerations, 695–6
symptom expression and, 132, 137–43
symptom overlap in, 70, 164–8, 303, 304, 307, 318, 413, 421, 457, 640, 738–9
trauma- and stress-related disorders diagnostic considerations, 413
treatments and interventions based on, 675
validity of, 107, 108, 109, 111–12, 121, 123, 126, 127, 776, 777
Diagnostic and assessment tools:
Acute Stress Disorder Interview (ASDI), 414
Acute Stress Disorder Scale (ASDS), 414
Addiction Severity Index (ASI), 700, 702, 713
Addiction Severity inventory, 166
Adolescent Dissociative Experiences Scale (AD-DES), 463
Alcohol Dependence Scale (ADS), 677
Alcohol Use Disorders Identification Test (AUDIT), 65, 677
Anorexia Nervosa Inventory for Self-Rating (ANIS), 504
Anxiety Disorders Interview Schedule for DSM-5 (ADIS-5), 113, 114, 115–16, 309, 366, 414
Anxiety Disorders Interview Schedule for DSM-5–Lifetime (ADIS-5-L), 116
Anxiety Sensitivity Index-3 (ASI-3), 39, 310, 437, 442
BDD Examination (BDDE), 366
Beck Anxiety Inventory (BAI), 437, 442, 678
Beck Depression Inventory (BDI), 9, 678
Beck Depression Inventory-II, 265, 437, 442
<table>
<thead>
<tr>
<th>Diagnostic and assessment tools (Continued)</th>
<th>Beck Depression Inventory-Primary Care (BDI-PC), 266</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beck Suicidality Scale, 65</td>
<td>behavioral avoidance tests (BATs), 366</td>
</tr>
<tr>
<td>Binge Eating Scale (BES), 504</td>
<td>blood analysis, 703–4</td>
</tr>
<tr>
<td>Brief Fear of Negative Evaluation Scale (BFNES), 310</td>
<td>breath analyzer, 680</td>
</tr>
<tr>
<td>Brief Psychiatric Rating Scale (BPRS), 170</td>
<td>Brief Situational Confidence Questionnaire (BSCQ), 678</td>
</tr>
<tr>
<td>Brixton Task, 519</td>
<td>Cambridge Depersonalization Scale (CDS), 457, 465</td>
</tr>
<tr>
<td>CAGE, 700</td>
<td>CatBat Task, 519</td>
</tr>
<tr>
<td>Camberwell Family interview, 172</td>
<td>Center for Epidemiological Studies-Depression Scale (CES-D), 265</td>
</tr>
<tr>
<td>Circumstances, Motivation, Readiness, and Suitability (CMRS) Scales, 701</td>
<td>Clarke Sexual History Questionnaire for Males, 607</td>
</tr>
<tr>
<td>Clinician Administered Dissociation State Scale (CADSS), 462</td>
<td>Clinician-Administered PTSD Scale (CAPS), 414</td>
</tr>
<tr>
<td>Cultural Formulation Interview (CFI), 126–7</td>
<td>Dartmouth Assessment of Lifestyle Instrument (DALI), 166</td>
</tr>
<tr>
<td>Diagnostic Interview Schedule (DIS), 113, 502</td>
<td>Diagnostic Interview Schedule for DSM-IV (DIS-IV), 114</td>
</tr>
<tr>
<td>Diagnostic Interview Schedule for DSM-5 (DIS-5), 112, 116–18</td>
<td>Dimensional Assessment of Personality Pathology, 773</td>
</tr>
<tr>
<td>Dimensional Assessment of Personality Problems, 763</td>
<td>Dissociation Questionnaire (DIS-Q), 464</td>
</tr>
<tr>
<td>Dissociative Disorders Interview Schedule (DDIS), 461–2</td>
<td>Dissociative Experiences Scale (DES), 462</td>
</tr>
<tr>
<td>Dissociative Experiences Scale-Taxon (DES-T), 463</td>
<td>Drug Abuse Screening Test (DAST), 700</td>
</tr>
<tr>
<td>Drug Use Screening Inventory (DUSI), 702</td>
<td>Eating Attitudes Test (EAT), 522</td>
</tr>
<tr>
<td>Eating Disorder Examination (EDE), 502–3</td>
<td>Eating Disorder Examination-Questionnaire (EDE-Q), 503, 504</td>
</tr>
<tr>
<td>Eating Disorder Inventory (EDI), 503</td>
<td>Eating Disorder Inventory-2 (EDI-2), 503–4</td>
</tr>
<tr>
<td>Eating Disorder Inventory-3 (EDI-3), 504</td>
<td>Family Environment Scale, 172</td>
</tr>
<tr>
<td>Family Experiences Interview Schedule, 172–3</td>
<td>Fear of Negative Evaluation Scale, 38</td>
</tr>
<tr>
<td>Fear Survey Schedule-Second Edition (FSS-II), 310</td>
<td>functional analysis, 702, 713</td>
</tr>
<tr>
<td>Gender Identity/GD Questionnaire for Adolescents and Adults, 644</td>
<td>General Behavior Inventory (GBI), 221</td>
</tr>
<tr>
<td>General Health Questionnaire (GHQ), 266–7</td>
<td>Generalized Anxiety Disorder Questionnaire-DSM-IV (GAD-Q-IV), 310</td>
</tr>
<tr>
<td>Geriatric Depression Scale (GDS), 266</td>
<td>Gudjonsson Suggestibility Scale (GSS), 476</td>
</tr>
<tr>
<td>hair analyses, 680, 703</td>
<td>Hamilton Anxiety Rating Scale, 115</td>
</tr>
<tr>
<td>Hamilton Rating Scale for Depression, 115, 678</td>
<td>Haptic Illusion, 519</td>
</tr>
<tr>
<td>Health Anxiety Questionnaire, 437</td>
<td>Hypomanic Personality Scale, 221</td>
</tr>
<tr>
<td>Hoarding Rating Scale-Interview (HRS-I), 367</td>
<td>intelligence Quotient (IQ), 18–19</td>
</tr>
<tr>
<td>Hoarding Rating Scale-Self Report (HRS-SR), 369</td>
<td>international Personality Disorder Examination (IPDE), 112, 114, 122–3</td>
</tr>
<tr>
<td>Hospital Anxiety and Depression Scale (HADS), 265</td>
<td>interview for Diagnosis of Eating Disorders (IDED), 502</td>
</tr>
<tr>
<td>inventory of Drug Use Consequences (IndUC), 701, 702</td>
<td>inventory of Personality Organization, 773</td>
</tr>
</tbody>
</table>
| Kiddie Schedule for Affective Disorders | }
and Schizophrenia (KSADS), 224

LEAD (Longitudinal, Expert, All Data) standard, 773

Level of Personality Functioning scale, 782, 784

life-charting strategies, 224

lifetime drinking history (LDH), 676

Maryland Assessment of Social Competence (MASC), 171

Massachusetts General Hospital Hairpulling Scale (MGH-HPS), 367

Millon Clinical Multiaxial Inventory-III, 678

Milwaukee Inventory for Subtypes of Trichotillomania-Adult Version (MIST-A), 367

Milwaukee Inventory for the Dimensions of Adult Skin Picking (MIDAS), 368

Mini-International Neuropsychiatric interview (MINI), 268

Mini-International Neuropsychiatric interview-Screen (MINI-Screen), 268

Minnesota Multiphasic Personality inventory, 9

Minnesota Multiphasic Personality inventory-2, 644, 678

Montgomery Asberg Depression Rating Scale (MADRS-S), 265

Multiaxial Assessment of Eating Disorder Symptoms (MAEDS), 504

Multidimensional Inventory of Dissociation (MID), 464

Multiphasic Sex Inventory, 607

Multiple Sleep Latency Test (MSLT), 552, 555

NIMH-Life Charting method, 224

NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (NIMH-MATRICS), 170

observational tasks, 366

Obsessive-Compulsive Inventory-Revised (OCI-R), 366

Panic and Agoraphobia Scale (PAS), 310

Panic Disorder Severity Scale (PDSS), 310

Patient Health Questionnaire-2, 265

Patient Health Questionnaire-9 (PHQ-9), 265, 266

Patient Health Questionnaire-15, 437

Penn State Worry Questionnaire (PSWQ), 310

Personality Disorder Questionnaire, 772

phallometry, 607–8

Phobic Stimuli Response Scales, 310

polygraph testing, 608–9

Positive and Negative Syndrome Scale (PANSS), 170

Posttraumatic Diagnostic Scale (PDS), 414

Primary Care Evaluation of Mental Disorders (PRIME-MD), 266

Profile of Mood States (POMS), 265

Psychodynamic Diagnostic Manual (PDM), 773

Psychotic Rating Scale (PSYRATS), 170

PTSD Checklist, 414

PTSD Symptom Scale– Interview (PSS-I), 414

question-frequency methods (QF), 676

Questionnaire for Eating and Weight Patterns-Revised (QEWP-R), 504

Readiness Ruler, 679

Rejection Sensitivity Questionnaire, 783

Relationship Questionnaire, 784

Rorschach Inkblot Method, 774

saliva analysis, 703

Saving Inventory-Revised (SI-R), 367

Scale for the Assessment of Negative Symptoms, 170

Scale for the Assessment of Positive Symptoms, 170

Schedule for Affective Disorders and Schizophrenia (SADS), 112, 113, 118–19

Schedule for Nonadaptive and Adaptive Personality, 763, 773

Schedules for Clinical Assessment in Neuropsychiatry, 437

Screening for Somatoform Symptoms, 437

Set Flexibility Picture Test, 678

Severity of Alcohol Dependence Questionnaire (SADQ), 677

Sexual Deviance Card Sort, 607

Sexual Interest Card Sort Questionnaire, 607

Shedler and Westen Assessment Procedure (SWAP), 773

Short Alcohol Dependence Data Questionnaire (SADD), 677

Situational Confidence Questionnaire (SCQ-39), 678

Skin Picking Scale (SPS), 368

Social Functioning Scale, 172
Diagnostic and assessment tools (Continued)

Social Interaction Anxiety Scale (SIAS), 310
Social Phobia and Anxiety inventory (SPAI), 310
Social Phobia Scale (SPS), 310
Somatoform Disorders Schedule, 437
Somatoform Dissociation Questionnaire (SDQ-20), 464
Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES), 701
State Scale of Dissociation (SSD), 464–5
Stirling Eating Disorder Scales (SEDS), 504
Structured Clinical Interview for DSM (SCID), 119–21, 224, 414
Structured Clinical Interview for DSM-5 Disorders, 442, 700
Structured Clinical Interview for DSM-5 (SCID-5), 57, 113, 114, 119–21, 224, 267, 309–10, 437
Structured Clinical Interview for DSM-IV, 502
Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II), 124
Structured Clinical Interview for DSM-IV-Revised (SCID-D-R), 461
Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-5-CV), 366
Structured Clinical Interview for DSM-IV-TR Axis II Personality Disorders (SCID-II), 772
Structured Interview for Anorexic and Bulimic Disorders (SIAB-EX), 502, 503
Structured Interview for DSM-IV Personality Disorder (SIDP-IV), 112, 114, 122, 124–5, 126
Structured Interview for PTSD (SI-PTSD), 414
Structured Interview of Personality Organization, 773
sweat testing, 703–4
Symptom Checklist 90-Revised (SCL-90-R), 437, 678
Temperament Evaluation of Memphis, Pisa, Paris, and San Diego (TEMPS-A), 221
Thematic Apperception Test, 774
Three Factor Eating Questionnaire (TFEQ), 504
Timeline Followback (TLFB), 676, 687, 701
Trail Making Test (TMT), 519, 679
UCSD Performance-Based Skills Assessment (UPSA), 172
University of Rhode Island Change Assessment (URICA), 701
urinalyses, 679–80, 703
Utrecht GD Scale, 644
Uznadze Illusion Task, 519
visual reaction time, 609
Wechsler Adult Intelligence Scale, 475
Wechsler Adult Intelligence Scale (WAIS-IV), 678–9

dependent)</dependency>

Diagnostic and Statistical Manual of Mental Disorders (DSM):

alcohol use disorders in, 669–70
anxiety disorders in, 299–306
bipolar disorder in, 209–11, 220, 221, 222–3s
depressive disorders in, 248, 250, 252, 256–61, 263, 264, 265, 267, 268, 279
dimensional vs. categorical classification in, 3–24, 304, 775
DSM-I, 33, 672, 764–5

Wechsler Memory Scale (WMS-IV), 679
Whiteley Index, 437, 442
Wilson Sex Fantasy Questionnaire, 607
Wisconsin Card Sorting Test, 519, 679
World Health Organization (WHO) Composite International Diagnostic Interview (CIDI), 10, 52, 118, 267, 437, 502
World Health Organization Well-Being Index (WHO-5), 266–7
Yale-Brown Obsessive-Compulsive Scale-BDD (BDD-Y-BOCS), 366
Yale-Brown Obsessive-Compulsive Scale - Second Edition (Y-BOCS-II), 366
Yale-Brown Obsessive-Compulsive Scale - Self Report, 366
Y-BOCS modified for Body Dysmorphic Disorder (BDD-YBOCS), 366
Zung Self-Rating Depression Scale, 9, 265
DSM-II, 33, 458, 764–5
DSM-II-R, 58, 59
DSM-III, 4, 5, 7, 14, 20–1, 22, 33, 301, 435, 633, 634, 757, 758, 765–6, 767, 774, 775, 777
DSM-III-R, 5, 6, 7, 11, 14, 33, 58, 259, 260, 300–1, 435, 634, 637, 673, 766
Differential diagnosis:
od of anxiety disorders, 304–5
of attention deficit/ hyperactivity disorder, 223
of bipolar disorder, 166, 220–4
of clinical disorders, generally, 105
of delusional disorder, 167–8
of depressive disorders, 166–7, 261, 738–9
dimensional vs. categorical classification, 3, 5
of dissociative disorders, 460
of feeding and eating disorders, 502–3
of gender dysphoria, 640
of obsessive-compulsive disorders, 364
of personality disorders, 105, 106, 111, 112, 121–7, 7, 777
of schizoaffective disorder, 167–8
of schizophrenia, 164–8
of sexual dysfunctions and paraphilic disorders, 603–4
of sleep disorders, 553–4, 555, 557, 559, 560, 562
of somatic symptom and related disorders, 433–4
substance use disorders:

alcohol in, 669–70, 672–3, 675, 677, 687

drugs in, 695–6

trauma- and stress-related disorders in, 409–13, 418

Dialectical behavior therapy (DBT):

for dissociative disorders, 467
for obsessive-compulsive disorders, 384
for personality disorders, 771

Differential diagnosis:

of anxiety disorders, 304–5
of attention deficit/ hyperactivity disorder, 223
of clinical disorders, generally, 105
of delusional disorder, 167–8
of depressive disorders, 166–7, 261, 738–9
dimensional vs. categorical classification, 3, 5
of dissociative disorders, 460
of feeding and eating disorders, 502–3
of gender dysphoria, 640
of obsessive-compulsive disorders, 364
of personality disorders, 105, 106, 111, 112, 121–7, 7, 777
of schizoaffective disorder, 167–8
of schizophrenia, 164–8
of sexual dysfunctions and paraphilic disorders, 603–4
of sleep disorders, 553–4, 555, 557, 559, 560, 562
of somatic symptom and related disorders, 433–4
structural and semistructured interviews for, 105–27
of substance use disorders, 165–6
Differential diagnosis  
(Continued)  
of trauma- and stress- 
related disorders, 413,  
420–1  
Disruptive behavior 
disorders. See Conduct 
or disruptive behavior 
disorders  
Disruptive mood 
dysregulation disorder  
(DMDD), 222  
Dissociative amnesia:  
continuous, 454  
crime-related, 455  
description of, 451, 454–5  
epidemiology of, 454–5  
generalized, 454  
localized, 454  
posttraumatic vs.  
sociocognitive model  
of, 474–80  
psychological assessments  
of, 463  
selective, 454  
systematized, 454  
Dissociative disorders:  
age influences and  
differences in, 454  
biological considerations  
for, 468–70  
borderline personality  
disorder comorbidity  
with, 462, 474  
case study of, 466–7  
cognitive-behavioral  
therapy for, 467  
compartmentalization in,  
453  
depersonalization/  
derealization disorder  
as, 451, 452, 453, 457–8,  
461, 462, 463, 465, 466,  
468–9, 478  
depressive disorder  
comorbidity with, 457  
description of, 451–4  
detachment in, 452, 453  
diagnostic considerations  
for, 454, 455  
dialectical behavior therapy  
for, 467  
dimensional vs. categorical  
classification of, 6  
dissociative amnesia as,  
451, 452, 453, 454–5,  
456, 463, 476  
dissociative fugue as, 455–6  
dissociative identity  
disorder as, 451, 452,  
458–61, 478–80, 640  
eating disorder  
comorbidity with, 461,  
462  
environmental risk factors  
for, 466–7, 470  
epidemiology of, 452, 454–5,  
456, 458, 460–1  
etiological considerations  
for, 451, 452–3, 467–70,  
476, 478  
gender dysphoria  
comorbidity with, 640  
gender influences and  
differences in, 455  
genetic risk factors for, 467  
hypnosis with, 465, 467,  
472, 473  
learning and modeling of,  
470  
mindfulness approaches  
for, 467  
other specified dissociative  
disorder as, 452  
pharmacologic  
treatments and  
interventions for, 478,  
479  
somatic dissociation, 451,  
454  
structured and  
semistructured  
interviews on, 461–2  
substance use comorbidity  
with, 457, 460  
suicide/suicide ideation  
comorbidity with, 456,  
459  
symptom overlap with,  
460, 475, 477, 640  
Dissociative fugue, 455–6  
Dissociative identity disorder  
(DID), 451, 452, 458–61,  
478–80, 640  
Drug interventions. See  
Pharmacologic  
treatments and  
interventions for, 478,  
479  
Drug use disorders. See  
Substance use  
disorders: alcohol;  
Substance use  
disorders: drugs  
Dual diagnosis. See also  
Comorbidity  
anxiety disorders in, 50–9,  
63, 66, 69, 70, 71, 82, 83  
bidirectional models on, 82  
bipolar disorder in, 48, 52,  
53, 55–6, 57, 58, 60, 61–2,  
64–5, 66, 70, 75, 77,  
223–4  
clinical impacts of, 59–70  
clinical studies of, 55–9  
common factors models on,  
74, 75–6  
community sample  
prevalence of, 48–50  
complexity of, 50, 54–5, 74, 82, 83  
conduct or disruptive  
behavior disorders in,  
75, 76  
cross-national  
epidemiological  
epidemiological  
studies of, 52–3  
depressive disorders in, 46,  
48, 50, 52, 54, 55–7,  
58–61, 65, 66, 69, 70, 72,  
75, 77, 79, 80–1, 259
diagnosis and assessment impacted by dual disorders, 70–2, 72–4, 433–4
epidemiological studies of, 46, 48–55
feeling and eating disorders in, 56, 57
functioning relationship to, 59–63, 64, 70, 71, 75–6, 77, 79, 81
future directions in, 82–4
gambling disorders in, 47–8, 51
gender dysphoria in, 640–2
genetic risk factors for, 75
health-care costs impacted by, 65
homelessness associated with, 68
legal problems or criminality as factor in, 60, 68
methodological issues in, 45–8
obsessive-compulsive disorders in, 48, 52, 56, 59, 71
overview of, 45
Persistence over time, 50, 53
personality disorders in, 48, 52, 54, 56–7, 58–9, 60, 70
physical illness risks in, 67–8, 83
psychopathology research impacted by, 72–4, 83
psychoses or psychotic disorders in, 53, 55, 63, 67
Sample selection influencing findings for, 46, 72–4
schizophrenia in, 46, 48, 49, 52, 53, 55, 57, 60–5, 68–9, 70, 71, 75, 77–80, 81–2
secondary psychiatric disorder models on, 80–2
secondary substance abuse models on, 76–80
service utilization impacted by, 65–7

single definition of, lack of, 47–8
somatic symptom and related disorders in, 433–4
structured interviews for, 45, 47, 57
substance use disorders: alcohol, 46–84
substance use disorders: drugs, 46–84
symptom overlap in, 70
theories of, 74–82
trauma- and stress-related disorders in, 46, 56–7, 59, 60–1, 64, 65, 67–8, 70, 77–8
Treatment noncompliance and, 63–5
Treatments and interventions impacted by, 63–5, 65–6, 68
violence associated with, 63–5
women with, 68–9

Dyspareunia, 576, 592
Dysthymic disorder. See Persistent depressive disorder
Dysthymia, see Persistent depressive disorder
Eating disorders. See Feeding and eating disorders
Ecological Momentary Assessment (EMA), 702
Environmental risk factors: for anxiety disorders, 327–8
for bipolar disorder, 214–15
for depressive disorders, 252, 263–4, 276–7
for dissociative disorders, 470
for feeding and eating disorders, 505–6, 515–17
for gender dysphoria, 650, 653
for obsessive-compulsive disorders, 374–6
for personality disorders, 768–9, 770–1
for schizophrenia, 170, 172, 174–5, 176–8, 184
for sexual dysfunctions and paraphilic disorders, 610–11
for somatic symptom and related disorders, 438
for substance use disorders: alcohol, 415, 682–4
for substance use disorders: drugs, 705, 706, 712
for trauma- and stress-related disorders, 416–17
Epidemiologic Catchment Area Study (ECA), 48–9, 50, 65, 259, 413
Erectile disorder (ED) 572, 575, 581, 583–4, 588–9, 594
EROS Clitoral Therapy Device, 589, 592
Error-related negativity (ERN), 39–40
Estonian Children Personality, Behaviour and Health Study, 517
Ethnicity. See Racial, ethnic and cultural factors
Etiological considerations: for anxiety disorders, 318–30
for bipolar disorder, 225–7
for depressive disorders, 268–74
for dissociative disorders, 451, 452–3, 467–70, 476, 478
for feeding and eating disorders, 505–22
for gender dysphoria, 649–54
for neurocognitive disorders, 741–750
for obsessive-compulsive disorders, 368–85
for personality disorders, 768–70
for schizophrenia, 174–81
for sexual dysfunctions and paraphilic disorders, 583–7, 609–11
Etiological considerations
(Continued)
for bipolar disorder, 219, 220
for feeding and eating disorders, 507
Feeding and eating disorders:
age influences and differences in, 497, 498, 523
anxiety comorbidity with, 500, 522
atypical anorexia nervosa, 501
avoidant/restrictive food intake disorder as, 497
binge-eating disorder as, 56, 497, 505–6, 509–10, 512, 513, 515, 518–19, 520–1, 522, 524
bipolar disorder
comorbidity with, 57
case study of, 524–6
clinical picture of, 497–9
cognitive-behavioral therapy for, 522, 523
cognitive functioning with, 518–21
costs of, 523
course and prognosis of, 522–4
depression comorbidity with, 500, 522
description of, 497
diagnostic considerations for, 499–500
dimensional vs. categorical classification of, 6
dissociative disorder
comorbidity with, 460
dual diagnosis including, 56, 57
environmental risk factors for, 506, 507, 515, 517, 518
epidemiology of, 501
etiological considerations for, 505–22
family-based therapy for, 507
future research in, 526
gender influences and differences in, 498, 501
521–2
genetic risk factors for, 497, 506, 507–10, 511, 515
hospitalization for, 523–4
interpersonal therapy for, 523, 524
learning and modeling of, 515–18
life functioning with, 500
medical assessment, 504–5
neuroanatomy and neurobiological function with, 510–15, 518, 519
night eating syndrome, 499
obesity and, 500, 505, 509, 519, 526
other specified feeding or eating disorder (OFSED), 499
personality disorder comorbidity with, 500
personality traits with, 500, 506, 520
pharmacologic interventions for, 523, 524
pica as, 497
post-traumatic stress disorder comorbidity with, 517
psychological and biological assessments of, 501–5
purging disorder as, 499
racial, ethnic and cultural factors in, 133, 521–2
rumination disorder as, 497
self-reports 503–4
structured and semistructured interviews on, 502–3
substance use comorbidity with, 56, 57, 500, 709

European Outcome of Depression International Network, 413
Excoriation disorder (ED):
case study of, 389–90
clinical features of, 363
description of, 360
genetic risk factors for, 369, 370
neurobiological function with, 373
as obsessive-compulsive related disorder, 120, 359, 360, 363, 369, 370, 373, 389–90
structured and semistructured interviews on, 120
Exhibitionistic disorder, 597–8, 604, 606, 612–13
Exposure therapy:
for anxiety disorders, 314, 317
Prolonged Exposure as, 418
racial, ethnic and cultural variations of, 137–8
for trauma- and stress-related disorders, 417, 418
Eye movement desensitization and reprocessing (EMDR), 315
Factitious disorder, 429, 432–3
Family assessments, for schizophrenia, 172–3
Family-focused therapy (FFT):
for bipolar disorder, 219, 220
for feeding and eating disorders, 507
treatments and interventions for, 522–4
Female orgasmic disorder (FOD):
clinical picture of, 575
course, prognosis and treatment for, 589
description of, 572, 574
epidemiology of, 579, 581
etiological considerations for, 584
Female sexual interest/arousal disorder (FSIAD):
clinical picture of, 575–6
course, prognosis and treatment for, 590–2
description of, 572
epidemiology of, 579
etiological considerations for, 584–5
Fetishistic disorder, 598, 603, 605–6
Fibromyalgia, 438
"Frenzy" witchcraft, as culturebound syndrome, 456
Frontotemporal neurocognitive disorder, 727, 731–2
Frotteuristic disorder, 598–9, 604, 605
Functional neurological symptom disorder. See Conversion disorder
Functioning:
cognitive functioning (see Cognitive functioning)
community functioning, 170, 172, 182
dual diagnosis relationship to, 59–63, 64, 70, 71, 75–6, 77, 79, 81
life functioning (see Life functioning)
neurobiological function (see Neurobiological function)
social functioning (see Social functioning)
Galen, 764
Gambling disorders:
age influences and differences in, 54
diagnostic and assessment tools addressing, 120
dimensional vs. categorical classification of, 11
dual diagnosis including, 47–8, 51
Gender dysphoria:
acceptance of natal gender in, 645
age influences and differences in, 636–9, 643
anxiety comorbidity with, 640
bipolar disorder comorbidity with, 640
case study of, 55–6
clinical picture of 635–9
cognitive functioning with, 653–4
course and prognosis of, 645–6
depression comorbidity with, 640
description of, 633–5
diagnostic considerations for, 639–42
disorders of sexual development as, 643
dissociative disorder comorbidity with, 640
environmental risk factors for, 653
epidemiology of, 642–3
etiological considerations for, 649–54
full-time cross-living in, 645–6
gender influences and differences in, 636, 637–9, 640, 641, 642–3, 644, 645, 647–8, 649–50, 651–2
genetic risk factors for, 649–50
history and terminology of, 633–5
homosexual females with, 637
homosexual males with, 637–8
hormone therapy for, 640, 642, 645–7, 648, 650–2, 654, 655, 656
intersexual condition, 636
karyotyping in, 644
learning and modeling of, 653
neurobiological function in, 650–3
nonhomosexual females with, 638
nonhomosexual males with, 639, 653
other specified, 635, 639
part-time cross-gender behavior in, 45
personality disorder comorbidity with, 640, 641
psychological and biological assessments of, 643–4
psychoses or psychotic disorder comorbidity with, 640, 643
psychotherapy for, 645, 646, 655, 656
racial, ethnic and cultural factors in, 654
real-life experience in desired gender role in, 646
schizophrenia comorbidity with, 640
sex reassignment for, 633, 635, 637–8, 640, 642, 643, 645–6, 647, 648–9, 655, 656
sexual dysfunctions and paraphilic disorders comorbidity with, 602, 604, 635
sexual orientation and, 636–9, 643, 651, 652, 654, 656
standards of care for, 646
substance use comorbidity with, 641
subtypes, 636–9
suicide/suicide ideation comorbidity with, 641, 647, 649
transgenderism as, 635, 636
transsexualism as, 633–56
Gender dysphoria
(Continued)
transvestic disorder
association with, 602, 604, 640, 643, 649, 655
treatments and interventions for, 633, 636, 639, 640, 642, 644, 645–9, 655, 656
unresolved or unknown outcomes in, 645
unspecified, 639
Gender influences and differences. See also Women
in bipolar disorder, 212
in depressive disorders, 261, 277–8
in dissociative disorders, 455
in feeding and eating disorders, 497, 498, 501
in obsessive-compulsive disorders, 379–81
in paraphilic disorders, 597–8, 600, 601, 602, 604, 612
in schizophrenia, 179, 183
in sexual dysfunction (see gender-specific sexual dysfunctions)
in sleep disorders, 553, 560
in somatic symptom and related disorders, 439–40
in substance use disorders: alcohol, 68–9, 674, 681, 682, 684, 685, 687
in substance use disorders: drugs, 46, 68–9, 709
in trauma- and stress-related disorders, 417
Generalized anxiety disorder. See also Anxiety disorders
behavioral considerations for, 323–4
biological/neurobiological function with, 320–1
bipolar disorder comorbidity with, 223
cognitive-behavioral therapy for, 313–14
cognitive functioning with, 324–7
depression comorbidity with, 259, 307, 310
description of, 301–2
dual diagnosis including, 57
emotion dysregulation in, 302
epidemiology of, 306
etiological considerations for, 318–20
 Genetic risk factors for, 318, 321
 hoarding disorder comorbidity with, 364
 intolerance of uncertainty in, 301
 personality and temperament in, 322
 pharmacologic interventions for, 312–13
 racial, ethnic and cultural factors in, 136
 self-monitoring of, 311
 self-report measures for, 310
 sleep disorder comorbidity with, 554
 structured and semistructured interviews on, 309–10
 substance use comorbidity with, 57
 treatments and interventions for, 312, 313–14, 315–16
 Genetic risk factors:
 for anxiety disorders, 318, 321
 for bipolar disorder, 75, 225, 226
 common factors model focus on, 75–6
 for depressive disorders, 75–6, 269–70, 318
 for dissociative disorders, 467
for feeding and eating disorders, 507–10, 517–18
for gender dysphoria, 649–50
for intellectual disability, 749
for neurocognitive disorders, 725, 739, 740, 746–7, 749–50
for obsessive-compulsive disorders, 368–70
for personality disorders, 768–9
for schizophrenia, 75, 174–6
for sexual dysfunctions and paraphilic disorders, 583, 584, 585
for sleep disorders, 550, 555, 556, 558, 560, 561
for somatic symptom and related disorders, 438
for substance use disorders: drugs, 75–6, 704–5, 746–7, 749–50
for trauma- and stress-related disorders, 414–15
Genito-pelvic pain-penetration disorder (GPPPD):
clinical picture of, 576
course, prognosis and treatment for, 492–3
description of, 571
epidemiology of, 579
etiological considerations for, 585–6
Genito-pelvic pain-penetration disorder (GPPPD):
clinical picture of, 576
course, prognosis and treatment for, 492–3
description of, 571
epidemiology of, 579
etiological considerations for, 585–6
Georgia Health and Behavior Study, 9
Grief and bereavement, 10–11, 258
Guided Self-Change, 686
Habit reversal training, 379, 384
Hair analyses, 680, 703
Head trauma, 725–6, 727, 732, 733, 739, 741, 742–3, 750–1
Health and illness. See Mental disorders; Physical illnesses
Health-care costs:
of depressive disorders, 256
dual diagnosis impacting, 65
of feeding and eating disorders, 523
insurance coverage for, 14–15
of personality disorders, 757
of schizophrenia, 159
of somatic symptom and related disorders, 430
of substance use disorders:
drugs, 65, 695
Healthcare for Communities Survey, 66
Hepatitis C, 67
Heritability. See Genetic risk factors
Hippocrates, 764
Histrionic personality disorders:
case study of, 779
clinical picture of, 767
dsm-5 elimination of, 775, 776
epidemiology of, 768
etiological considerations for, 768
HiTOP
in personality disorders, 780
HIV and AIDS:
dual diagnosis impacting risk for, 67
neurocognitive disorders associated with, 725, 727, 733, 740, 749
Hoarding disorder (HD):
case study of, 387–8
clinical features of, 361, 362–3
cognitive functioning with, 376, 378
course and prognosis of, 383
description of, 360
diagnostic consideration for, 364
environmental risk factors for, 375
epidemiology of, 365
etiological considerations for, 368, 369–70, 376, 378
gender influences and differences in, 379, 381
genetic risk factors for, 369–70
neurobiological function with, 372–3
psychological and biological assessments of, 367
racial, ethnic and cultural factors in, 139, 379
structured and semistructured interviews on, 120, 367
treatments and interventions for, 383–4
Homelessness, 68, 160, 162, 163, 768, 778
Hormone therapy, 640, 642, 645–7, 648, 650–2, 654, 655, 656
Huntington’s disease, 725, 727, 733, 739, 740, 741, 746, 749, 750
Hypersexual disorder, 11
Hypersonolence disorder, 549, 554–6, 557
Hypnosis, 465, 467, 472, 473
Hypochondriasis, 6, 434–5, 438, 439, 440
illness anxiety disorder as, 429, 430, 431, 433, 434, 435–6
Illnesses. See Mental disorders; Physical illnesses
Impulse-dyscontrol disorders, 13, 15, 364. See also Conduct or disruptive behavior disorders
Insomnia disorder, 549, 552–4, 557, 559, 562, 563, 564
Institute of Medicine, 419
Insurance coverage, 14
Intellectual disability: course and prognosis of, 750–1
dimensional and categorical classification of, 12, 18–19
etiologies of, 19
genetic risk factors for, 749
neurocognitive disorder distinction from, 731
International Classification of Diseases:
alcohol use disorders in, 672
anxiety disorders in, 303
dimensional vs. categorical classification in, 13–14
dissociative disorders in, 464
gender dysphoria in, 635
ICD-6, 672
ICD-10, 13–14, 33, 122–3, 138, 259, 303, 437, 464, 503, 574, 635
ICD-11, 571, 574, 577, 613
personality disorders in, 779–80
rational, ethnic and cultural factors considered in, 138
sexual dysfunctions and paraphilic disorders in, 571, 574, 577, 613
structured and semistructured interviews based on, 122–3, 437, 503
International Classification of Sleep Disorders (ICSD-3), 549, 554, 555
Internet addiction, 11
Interpersonal
Hypersensitivity
RDoC Negative Valence System and, 781–3
Interpersonal therapy (IPT): for anxiety disorders, 315
for feeding and eating disorders, 523, 524
Interpersonal and social rhythm therapy (IPSRT) as, 218–19, 220
Interventions. See Treatments and interventions interviews. See Structured and semistructured interviews
Item response theory (IRT) methodology, 12–13
Jellinek, E. M., 671
Karyotyping, 644
Kleine-Levin syndrome, 554, 555, 560, 562
Kleinfelter syndrome, 644
Koro, as culture-bound syndrome, 138
Kraepelin, Emil, 764
Kuru, 749
Legal problems. See also Criminality consensual paraphilias not legal issue, 603
dual diagnosis consideration of, 60, 65, 68 sexual offenders and paraphilias, 597, 599, 603, 604, 611, 613
substance use disorders and, 60, 68
Leukoaraiosis, 739
Levy bodies disease, 727, 732
Liebowitz Social Anxiety Scale Self-Report, 784
Life events. See Environmental risk factors
Life functioning: anxiety disorders impacting, 304 bipolar disorder impacting, 213–14
depressive disorders impacting, 255
dual diagnosis impacting, 60–1
Longitudinal Study of Personality Disorder, 771
substance use among, specifically: drugs, 709 Mental disorders: anxiety (see Anxiety disorders) autistic, 7 bipolar (see Bipolar disorder) comorbidity of (see Comorbidity) conduct or disruptive behavior (see Conduct or disruptive behavior disorders) costs associated with (see Health-care costs) depressive (see Depressive disorders) diagnosis of (see Diagnosis and assessment) dissociative (see Dissociative disorders) feeding and eating (see Feeding and eating disorders) gender dysphoric (see Gender dysphoria) impulse-dyscontrol, 13, 15, 364 intellectual, 12, 18–19, 731, 749, 750–1 obsessive-compulsive (see Obsessive-compulsive anxiety disorders; Obsessive compulsive personality disorders) personality (see Personality disorders) psychotic (see Psychoses or psychotic disorders) racial, ethnic and cultural factors in (see Racial,
ethnic and cultural factors
schizophrenic (see Schizophrenia)
ssexual (see Sexual dysfunctions and paraphilic disorders)
sleep-related (see Sleep disorders)
somatic (see Somatic symptom and related disorders)
stigma associated with (see Stigmatization)
substance use (see Substance use disorders)
trauma- and stress-related (see Trauma- and stress-related disorders)
treatment for (see Treatments and interventions)
Mentalization-based therapy, 771
Mental retardation. See Intellectual disability
Meyer, Adolf, 764
Microcephaly, 19
Mindfulness approaches:
for anxiety disorders, 315
for dissociative disorders, 467
for sexual dysfunctions and paraphilic disorders, 589, 592, 593
Minorities, issues for. See Racial, ethnic and cultural factors
Mood disorders. See Bipolar disorder; Depressive disorders; Disruptive mood dysregulation disorder
Mosaicism, 19
Motivational interventions:
for substance use disorders, 672, 676, 679, 687
Multiple personality disorder. See Dissociative identity disorder
Multiple sclerosis, 434, 739, 741, 743, 745, 749
Multiple Sleep Latency Test (MSLT), 552
Munchhausen by proxy, 139
Narcissistic personality disorders:
clinical picture of, 766, 767
dual diagnosis including, 52
epidemiology of, 767, 768
etiological considerations for, 768
psychological assessments of, 775
separation of personality pathology and, 763
substance use comorbidity with, 52
Narcolepsy, 549, 552, 554, 555, 561
Narcotics Anonymous (NA), 713
National Center for PTSD, 414
National Coalition for Sexual Freedom, 603
National Comorbidity Survey (NCS), 9, 10, 49, 50, 51, 65, 256, 261, 435
National Comorbidity Survey Replication (NCS-R), 50, 51, 52, 57, 256, 261–2, 364, 412, 500
National Epiphiologidic
Survey on Alcohol and Related Conditions (NESARC), 50, 51, 52, 54, 57, 64, 673
National Health and Social Life Survey (NHSLS), 578
National Institute for Clinical Excellence (NICE), 523
National Institute of Mental Health (NIMH):
classification research by, 4, 21–2
Collaborative Program/Study on the Psychobiology of Depression, 56
Cognitive Neuroscience for Translational Research in Cognition on Schizophrenia (CNTRICS), 34
Course and Outcome of Bipolar Youth (COBY) study by, 222
DSM-5 criticism by, 21–2
Life Charting method, 224
Measurement and Treatment Research to Improve Cognition in Schizophrenia (NIMH-MATRICS), 170
Research Domain Criteria (RDoC) of, 21
Criterion of Systems for Social Processes, 781
critiques and responses, 37–9
examples, 39–41
matrix, 34–7
in personality disorders, 780–5
Strategic Plan, 34
structured interviews developed for, 116
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 674
National Institute on Drug Abuse Collaborative Cocaine Treatment Study, 59
National Institutes of Health (NIH) Joint Program for the Diagnosis and Classification of Mental Disorders, 122
National Latino and Asian Study (NLAAS), 132, 148, 263
National Longitudinal Alcohol Epidemiological Survey (NLAS), 48, 49–50, 65, 148
National Research Act, 147
National Survey of American Life (NSAL), 140, 263
National Survey of Veterans, 67
Neurasthenia, as culture-bound syndrome, 138–9
Neurobiological function. See also Cognitive functioning
in anxiety disorders, 320–1
in bipolar disorder, 226–7
in conversion disorder, 429, 431–2, 434, 436, 438
in depressive disorders, 270–3, 738–9
in dissociative disorders, 468–70, 475
dual diagnosis impacted by, 79
in feeding and eating disorders, 510–15, 518, 519
in gender dysphoria, 650–3
neurocognitive disorders impacting, 725–52
in obsessive-compulsive disorders, 370–4
in personality disorders, 769
in schizophrenia, 79–80, 176, 182, 475
in sexual dysfunctions and paraphilic disorders, 609–10, 651
in sleep disorders, 550, 558, 560
in somatic symptom and related disorders, 438
in substance use disorders: alcohol, 681–2, 746
in substance use disorders: drugs, 706, 707–9, 746
in trauma- and stress-related disorders, 415–16
Neurocognitive disorders:
acalculias as, 734
age influences and differences in, 731, 733, 739, 740, 741, 744–5, 750–1
agnosias or gnostic disorders as, 727, 735
agraphias as, 734
alcohol use and, 737, 739, 745–6, 749
alexias as, 734, 735
Alzheimer’s disease subtype of, 727, 732,
right-left disorientation as, 735
severity rating of, 726, 727
stigmatization of, 726, 731
stroke association with, 729, 732–3, 736, 739, 743–5, 750
substance/medication induced neurocognitive disorder as, 727, 733
Tay-Sachs disease association with, 748, 750
trauma- and stress-related disorder comorbidity with, 725, 743, 725–6, 727, 732, 733, 742, 743–4
treatments and interventions for, 747, 751
vascular neurocognitive disorder as, 727, 732–3, 744
viral infections association with, 748–9
Wernicke-Korsakoff syndrome association with, 747
Wernicke’s aphasia as, 734
Neurosyphilis, 748
New View Task Force, 572
New York High Risk Project, 182
Nicotine use disorders. See also Substance use disorders
dual diagnosis including, 47, 52, 57, 79–80, 79–80
substance use disinhibition as, 512–14, 516
substance use disinhibition as, 512–14, 516
substance use disinhibition as, 512–14, 516
substance use disinhibition as, 512–14, 516
substance use disinhibition as, 512–14, 516
Night eating syndrome, 499
Nightmare disorder, 549, 552, 554, 555, 561
Non-rapid eye movement (NREM) sleep arousal disorder, 549, 561–2
Obesity:
dual diagnosis including, 68, 83
diagnosis, 501
etiological considerations for, 509, 510, 519
feeding and eating disorders related to, 499, 500, 505, 509, 510, 519, 526
gene factors for, 509, 510
physical illnesses impacted by, 68, 508
sleep disorder comorbidity with, 553, 554
Obsessive-compulsive disorders. See also Anxiety disorders
acceptance and commitment therapy for, 384
age influences and differences in, 381–3
anxiety disorder comorbidity with, 364
bipolar disorder comorbidity with, 223
body dysmorphic disorder as, 6, 359, 360, 361, 364, 365, 366, 368–7, 640
case studies of, 385–90
clinical features of, 360–3
cognitive-behavioral therapy for, 382–4
cognitive functioning with, 376–9
cognitive restructuring for, 382
course and prognosis of, 381–5
depression comorbidity with, 362, 364
description of, 359–60
diagnostic considerations for, 363–5
dialectical behavior therapy for, 384
dimensional vs. categorical classification of, 6, 15
dual diagnosis including, 48, 52, 56, 59, 71
environmental risk factors for, 368–70, 375
epidemiology of, 366–6
etiological considerations for, 368–85
excoriation disorder as, 359, 360, 363, 369, 370, 373, 389–90
gender influences and differences in, 379–81
genetic risk factors for, 368–70
habit reversal training for, 379, 384–5
koro as culture-bound form of, 138
learning and modeling of, 374–6
life functioning with, 361, 362
neuroanatomy and neurobiological function with, 370–4, 376–8
pharmacologic interventions for, 382–3, 384
psychoeducation for, 383, 385
psychological and biological assessments of, 366–8
racial, ethnic and cultural factors in, 138–9, 379–81
structured and semistructured interviews on, 120, 366–8
substance use comorbidity with, 48, 51, 52, 56, 59, 364
suicide/suicide ideation comorbidity with, 362, 382, 386
Subject Index 869
Obsessive-compulsive disorders. See also Anxiety disorders (Continued)
treatments and interventions for, 382–5
trichotillomania as, 120, 359, 360, 367, 375, 384, 388–9
Obsessive-compulsive personality disorders: clinical picture of, 767
depressive disorder comorbidity with, 259
dimensional vs. categorical classification of, 15
dual diagnosis including, 52
epidemiology of, 767, 768
etiological considerations for, 770
hoarding criterion of, 367 (see also Hoarding disorder)
obsessive-compulsive anxiety disorder comorbidity with, 364
psychological assessments of, 775
substance use comorbidity with, 52
Pain disorders:
sexual, 571–2, 576, 581, 582, 585–6, 588, 592–3, 595–6
somatic, 429, 430–1, 435, 438
Panic disorder. See also Anxiety disorders
agoraphobia with, 300–1, 306, 317
behavioral considerations for, 323–4
biological/neurobiological function with, 318–21
bipolar disorder comorbidity with, 223
cognitive-behavioral therapy for, 313, 315–16
cognitive functioning with, 324–7
depression comorbidity with, 305, 317
diagnostic considerations for, 305, 306
dual diagnosis including, 48, 57, 59, 71, 82
epidemiology of, 305–6
etiological considerations for, 318–30
epilepsy, 263, 264
etiological considerations for, 320
etiological considerations for, 321
self-monitoring of, 311
self-report measures for, 310
sleep panic attacks, 562
structured and semistructured interviews on, 115, 309–10
substance use comorbidity with, 48, 57, 59, 71, 82, 305
treatments and interventions for, 309, 313, 315
Paranoid personality disorders:
clinical picture of, 766
DSM-5 elimination of, 775, 776
epidemiology of, 767, 768
etiological considerations for, 768
Paranoid schizophrenia, 147, 162, 180
Paraphilic disorders. See Sexual dysfunctions and paraphilic disorders
Parasomnias, 559, 560, 562.
See also Sleep disorders
Parkinson’s disease, 257, 727, 732, 733
Partial androgen insensitivity syndrome, 636
Passive-aggressive personality disorders, 765–6
Pedophilic disorder: clinical picture of, 599–600
diagnostic considerations for, 603, 604
epidemiology of, 604, 605
etiological considerations for, 609–10, 611
Performance anxiety, 582, 583, 584, 586, 587, 591
Peripartum depressive disorders, 252, 253
Persistent depressive disorder, 248, 249–50, 279, 280
Personality and temperament: in anxiety disorders, 322
anxiety sensitivity as, 322
behavioral inhibition and shy temperament as, 322–3
defining, 758–64
disorders of (see Personality disorders)
feeding and eating disorders related traits of, 500, 506–7, 520
heritability of, 768–9
neurocognitive disorders and, 732, 740, 748
personality dynamics, 760–1
personality traits, 759–60, 773
in posttraumatic stress disorder, 322
severity of personality pathology, 761–2, 763–4
Personality disorders:
age influences and differences in, 770
antisocial, 15, 48, 118, 640, 673, 698, 711, 758, 762, 765, 766, 768–9, 770, 775, 779
avoidant, 14–15, 59, 259, 303, 364, 457, 758, 762, 765, 767, 768, 770, 775
borderline, 15, 52, 57, 59, 247, 259, 457, 459, 461, 462, 466, 474, 673, 711, 757, 758, 760, 762, 763, 765, 766, 767, 768, 770–1, 775, 776, 778, 779–80, 781
boundaries with other mental disorders, 13–15
boundaries with other personality disorders and normal personality, 15–18
case study of, 777–80
clinical picture of, 766–7
clusters of, 758, 765
cognitive functioning with, 769–70
common factors model on, 75
costs of, 757
course and prognosis of, 770–1
defining personality for, 758–64
dependent, 758, 765, 767, 768, 775, 776
depressive, 6–8, 14
depressive disorder comorbidity with, 247, 259
description of, 758–9
diagnostic considerations for, 764–6
dialectical behavior therapy for, 771
dimensional vs. categorical classification of, 5, 6–9, 13–18, 20, 776
dissociative disorder comorbidity with, 459
dual diagnosis including, 48, 52, 54, 56–7, 58–9, 60, 70
environmental risk factors for, 768–9, 770–1
epidemiology of, 767–8
etiological considerations for, 768–70
feeding and eating disorders comorbidity with, 500
Five-Factor Model of personality domains, 16–17, 20, 759, 772–3, 784
gambling disorder comorbidity with, 54
gender dysphoria comorbidity with, 640
genetic risk factors for, 768–9
histrionic, 758, 765, 766, 767, 768, 775, 776, 779
mentalization-based therapy for, 771
multiple personality disorder (see Dissociative identity disorder)
narcissistic, 52, 758, 762, 763, 765, 766–7, 768, 775, 776
Research Domain Criteria (RDoC) in, 780–5
neurobiological function in, 769
obsessive-compulsive, 15, 52, 259, 364, 366, 367, 457, 758, 762, 765, 767, 768, 770, 775
obsessive-compulsive anxiety disorder comorbidity with, 364
paranoid, 758, 765, 766, 767, 768, 775, 776
passive-aggressive, 765–6
personality dynamics in, 760–1
personality traits in, 759–60, 772–3
pharmacologic interventions for, 771
psychoanalytic assessment of, 773–4
psychological assessments of, 771–7
research on, 767–71
schema-focused therapy for, 771
schizoid, 758, 765, 766, 768, 775, 776
schizotypal, 13–14, 52, 758, 762, 765, 766, 768, 769, 771, 775–6
separation of personality pathology and, 763–4
severity of personality pathology in, 761–2, 763–4
somatic symptom comorbidity with, 435, 440
stigmatization of, 14–15, 16
structured and semistructured interviews for, 105, 106–7, 111, 112, 118, 121–6, 127, 772
stylistic variability in expression of, 762–3, 769
substance use comorbidity with: alcohol, 49–50, 57–8, 59, 60, 61, 64–5, 68, 70, 71–3, 75, 80–1, 673, 778
substance use comorbidity with: drugs, 54, 62, 67, 73–4, 78, 79, 698, 778
suicide/suicide ideation comorbidity with, 757, 767, 778
symptom overlap with, 303, 457, 640
transference-focused therapy for, 771
trauma- and stress-related disorder comorbidity with, 57, 413
treatments and interventions for, 70, 757, 771, 777
Phallometry, 607–8
Pharmacologic interventions: for anxiety disorders, 312–13, 316–17
for bipolar disorder, 65, 212, 218, 226, 228
for depressive disorders, 10
for dissociative disorders, 478
for feeding and eating disorders, 523, 524
medication-induced depressive disorder, 248, 250–1, 258
subject index 871
Pharmacologic interventions 
(Continued)
medication-induced neurocognitive disorder, 727, 733, 739
medication-induced sexual dysfunction, 572, 577
medication-induced sleep disorder, 549
noncompliance with, 63–5, 148, 162–3, 218
for obsessive-compulsive disorders, 382–3, 385–6
for personality disorders, 771
racial, ethnic and cultural factors impacting, 148, 212
for schizophrenia, 64, 162, 163, 173, 176
for sexual dysfunctions and paraphilic disorders, 587–95, 596, 611
for sleep disorders, 479, 565
substance use impacting noncompliance with, 63–5
for trauma- and stress-related disorders, 419
Phenylketonuria (PKU), 748
Physical and sexual abuse:
dissociative disorders association with, 457, 459, 461, 466, 470, 471–3, 480
feeding and eating disorders association with, 515
obsessive-compulsive disorder association with, 374
paraphilic disorders association with, 600, 610–11
schizophrenia association with, 163, 179
sexual dysfunction association with, 584, 585, 600, 610
somatic symptom and related disorders association with, 438
trauma- and stress-related disorders association with, 412, 413, 415, 416, 471–80
of women with dual diagnosis, 69
Physical illnesses. See also specific illnesses
age influences and differences in, 68
depressive disorders relationship to, 251–2, 256–7
dual diagnosis impacting risk for, 67–8, 83
feeding and eating disorders association with, 500, 523–4
gender dysphoria hormone therapy association with, 647
neurocognitive disorders related to, 725–52
obesity impacting, 68, 524
psychological factors affecting other medical conditions, 433–4
sexual dysfunction and paraphilic disorder comorbidity with, 67, 572, 573, 577, 579, 582, 583–4
sleep disorder comorbidity with, 549, 552, 553, 554, 555–6, 557–8, 559, 560–1, 562
somatic symptom and related disorders comorbidity with, 434, 440
somatic symptoms presenting as (see Somatic symptom and related disorders)
substance use impacting: alcohol, 67–8
substance use impacting: drugs, 67–8
Physiological assessments. See Biological assessments
Physiotherapy, 586, 593
Pibloktok, as culture-bound syndrome, 456
Pica, 497
Pick’s disease, 745
PID-5, 782
Polycystic ovary syndrome
(PCOS), 644
Polygraph testing, 608–9
Polyneuritis, 747
Polysomnography, 551, 552, 555, 557, 559, 560, 562
Positive psychology, 255
Post-traumatic stress disorder
(PTSD):
antisocial personality disorder comorbidity with, 57
anxiety comorbidity with, 413
bipolar disorder comorbidity with, 223
case study of, 420
clinical features of, 411–12
cognitive-behavioral therapy for, 419
cognitive functioning with, 417
course and prognosis of, 417–19
depression comorbidity with, 413
description of, 409–10
diagnostic considerations for, 412–13
dissociation, post-traumatic model of, 451, 460, 471–80
dual diagnosis including, 56, 57, 59, 60, 61, 64, 65, 67, 68, 70, 77–8
environmental risk factors for, 416–17
epidemiology of, 413
etiological considerations for, 414–17
feeding and eating disorder comorbidity with, 517, 526
gender influences and differences in, 417
 genetic risk factors for, 414–15
learning and modeling of, 416–17
neurobiological function in, 415–16
neurocognitive disorder comorbidity with, 725, 743
oxytocin in treatment of, 785
personality and temperament in, 322
pharmacologic interventions for, 419
physical illnesses associated with, 68
psychological and biological assessments of, 414, 461–2
racial, ethnic and cultural factors in, 131, 142, 417
schizophrenia comorbidity with, 163–4
sleep disorder comorbidity with, 410, 558–9, 563–4
substance use comorbidity with, 56, 57, 59, 60, 61, 64, 65, 67, 68, 70, 77–8, 411, 709
suicide/suicide ideation comorbidity with, 65, 412, 413
susto comparison to, 137–8
symptom overlap with, 70, 411, 421
treatments and interventions for, 417–19
Prader-Willi syndrome, 19
Pregnancy:
dual diagnosis impacting, 69
obessive-compulsive disorder association with, 374
peripartum depressive disorders association with, 253
pseudocyesis with false belief of, 434
Premature (early) ejaculation (PE):
clinical picture of, 577
course, prognosis and treatment for, 594–5
description of, 572
epidemiology of, 581
etiological considerations for, 586–7
psychological and biological assessments of, 582–3
Premenstrual syndromes, 120, 139, 248, 250
Preparedness theory, 324
Prion disease neurocognitive disorders, 727, 733, 746
Project EAT, 515
Prolonged Exposure, 418. See also Exposure therapy
Pseudocyesis, 434
Pseudodementia, 738–9
Psychoanalytic psychotherapy, 315
Psychoeducation:
for anxiety disorders, 313
for bipolar disorder, 218
for obsessive-compulsive disorders, 385
for sexual dysfunctions and paraphilic disorders, 591, 596
for trauma- and stress-related disorders, 418
Psychological debriefing interventions, 419
Psychological/psychiatric disorders. See Mental disorders
Psychopathology research. See also specific studies
clinical studies, 45, 55–9
diagnosis and assessment importance in, 70–2, 109
dual diagnosis impacting, 70–2, 83
interpretation of, 74
on personality disorders, 767–71
rational, ethnic and cultural factors in, 146–7
Research Domain Criteria (RdoC) for, 21
sample selection in, 46, 72–4
structured and semistructured interviews used in, 105, 107, 109, 118, 119, 121
Psychoses or psychotic disorders. See also Schizophrenia
atypical, 55
cognitive functioning with, 64
depressive disorder comorbidity with, 253
dimensional vs. categorical classification of, 5, 6
dual diagnosis including, 53, 55, 63, 67
gender dysphoria comorbidity with, 640, 644
rational, ethnic and cultural factors in, 147–8
structured and semistructured interviews on, 118–19
substance-induced psychoses, 699
substance use comorbidity with: drugs, 53, 55, 63, 67
symptom overlap with, 70
Purging disorder, 499
Racial, ethnic and cultural factors:
acculturation as, 132–5
age cohort of minorities impacting, 136–137
in anxiety disorders, 131, 132, 134, 136, 140–1, 142, 145, 303, 328–9
for Asian Americans, 134, 135, 136, 140, 142, 262, 263, 278, 585, 681, 684
in attention deficit/hyperactivity disorder, 139
Racial, ethnic and cultural factors (Continued)
biculturalism as, 133
in bipolar disorder, 134, 212
clinician and client interplay impacted by, 143–4
color-blindness as response to, 144
cultural acknowledgment by clinician as, 145–6
in depressive disorders, 133, 134, 135, 136–7, 141, 142, 148, 256, 262–3, 278
diagnosis and assessment impacted by, 131–2, 133, 137–143, 146–7, 278
in dissociative disorders, 139, 454
ethnic identity as, 132–5, 136, 142
factor pattern investigations of, 137
in feeding and eating disorders, 133, 501, 521–2
in gender dysphoria, 654
language as, 133, 139, 143
microagression as response to, 145
misdiagnosis due to, 147–9
mistrust of medical institutions and establishment as, 146–7, 180
multiculturalism as, 144
for Native Americans, 456, 684
in neurocognitive disorders, 740, 750
in obsessive-compulsive disorders, 138, 139, 379–81
overview of, 131–2, 149
prevalence rates differing due to, 140

in psychoses or psychotic disorders, 147–8
race and discrimination as, 136, 140, 141–3, 145, 146, 147, 149
relevance in adult psychopathology, 132–5
in schizophrenia, 131–2, 147–8, 168, 179–81
in sexual dysfunctions and paraphilic disorders, 573, 579, 581, 583, 585, 688, 601
in sleep disorders, 554
sociocultural factors as, 75, 132, 135–7, 169, 328–9, 471–80, 506, 601, 671, 681, 684, 740
socioeconomic status of minorities as, 132, 135–136
in somatic symptom and related disorders, 139, 140, 439–40
somatization of distress as, 140–1
spirituality and religion as, 141, 180
stereotyping as, 136, 139, 144–5, 147, 148
stigmatization as, 140–1, 145
stressful life events as, 135, 142 (see also Environmental risk factors)
structured and semistructured interviews on, 138–9
in substance use disorders: alcohol, 134, 148, 671, 681, 684
in substance use disorders, drugs, 134, 148–9, 709–10
symptom expression impacted by, 132, 137–43
in trauma- and stress-related disorders, 131, 142, 417
treatments and interventions impacted by, 131–2, 134, 135–8, 141, 143–9, 180–1, 212, 709–10
Rapid eye movement (REM) sleep behavior disorder, 549, 559–61
Relaxation training:
for anxiety disorders, 314
for dissociative disorders, 467
for sexual dysfunctions and paraphilic disorders, 589, 596
for trauma- and stress-related disorders, 419
Reliability of diagnosis and assessment, 106, 108–9, 127
Research. See Psychopathology research
Research Domain Criteria (RDoC) of, 21
critiques and responses, 37–9
examples, 39–41
matrix, 34–7
in personality disorders, 780–5
Restless legs syndrome, 549, 553–4
Royal Australian and New Zealand College of Psychiatrists, 523
Rumination disorder, 497
Sadism. See Sexual sadism disorder
Saliva analysis, 703
Schema-focused therapy, 771
Schizoaffective disorder, 165, 166, 167–8, 460
Schizoid personality disorders: clinical picture of, 766
DSM-5 elimination of, 775, 776
epidemiology of, 768
etiological considerations for, 768
Schizophrenia:
age influences and differences in, 182–3
anxiety comorobidity with, 162, 170
behavioral family therapy for, 181
biological assessment of, 172
bipolar disorder
comorbidity with, 166
case study of, 184–6
clinical picture of, 160–4
cognitive functioning with, 61–3, 160, 161, 170, 178, 182
community functioning with, 170, 172, 182

coping skills training for, 177
costs of, 159
course and prognosis of, 181–4
delusional disorder
relationship to, 167–8
depression comorbidity with, 161, 166–7, 259
derivation of, 160
diagnostic considerations for, 164–8
dimensional vs. categorical classification of, 4, 6–7, 13–14
dissociative disorder
comorbidity with, 460
dual diagnosis including, 46, 48, 49, 52, 53, 55, 57, 60–5, 68–9, 70, 71, 75, 77–80, 81–2
environmental risk factors for, 170, 172, 174–5, 176–8, 184
epidemiology of, 168–9
etiological considerations with, 174–84
eye tracking deficits in, 80
family assessment in, 172–3
gender dysphoria
comorbidity with, 640
gender influences and differences in, 179, 183
genetic risk factors for, 75, 174–6
homelessness associated with, 68, 160, 162, 163
learning and modeling, 176–8
life functioning with, 60–1, 159, 160, 167–8

neuroanatomy and neurobiology in, 79–80, 176, 182, 475
overview of, 159–60, 187
paranoid, 147, 162, 180
pharmacologic interventions for, 65, 162–3, 176, 184, 186
physical illnesses associated with, 68
post-traumatic stress disorder comorbidity with, 163–4
psychological assessment of, 162, 163, 173, 176
racial, ethnic and cultural factors in, 131–2, 147–184

schizoaffective disorder
relationship to, 165, 166, 167–8
schizotypal personality disorder relationship to, 13–14
self-medication for, 76–9, 82
social functioning with, 160, 170–2, 178, 183
social skills training for, 178
stigma of, 179, 181
structured and semistructured interviews on, 111, 112, 118–19, 164, 168, 170–2
substance use comorbidity with: alcohol, 54, 62, 67, 73–4, 78, 162, 165–6, 187

symptom overlap with, 70, 164–8, 475
treatment noncompliance in, 162–3
treatments and interventions for, 65, 162–3, 173, 176, 178, 180–1
violence and, 163

Schizotypal personality disorders:
clinical picture of, 758
dimensional vs. categorical classification of, 13–14
dual diagnosis including, 52
epidemiology of, 768
etiological considerations for, 769
pharmacologic interventions for, 771
psychological assessments of, 775
substance use comorbidity with, 52
Selective mutism, 303
Self-Awareness Model, 683
Self-monitoring:
of anxiety disorders, 311
of somatic symptom and related disorders, 437
of substance use disorders: alcohol, 675–6
Separation anxiety disorder, 364
Sexual dysfunctions and paraphilic disorders. See also Gender dysphoria
age influences and differences in, 578–81, 584, 588, 599–600
anxiety comorbidity with, 577, 582, 584, 586, 587, 589, 591
autogynephilia as, 602
biological assessments of, 582–3, 606–7
case study of, 595–6, 612–13
clinical picture of, 574–7, 597–603
cognitive-behavioral therapy for, 589, 591, 593, 611, 613
cognitive functioning with, 611
course and prognosis of, 587–95, 611
delayed ejaculation as, 572, 574, 579–80, 583, 584, 587
Subject Index 875
Sexual dysfunctions and paraphilic disorders. See also Gender dysphoria (Continued)
depression comorbidity with, 573, 579, 584, 586, 588
description of, 571–4, 596, 597
diagnostic considerations for, 578, 603–4
dissociative disorder comorbidity with, 460
dyspareunia as, 576, 592
environmental risk factors for, 610–11
epidemiology of, 578–81, 604–6
erectile disorder as, 572, 575, 581, 583–4, 588–9, 594
etiological considerations for, 583–7, 609–11
exhibitionistic disorder as, 597–8, 604, 606, 612–13
female orgasmic disorder as, 572, 574, 575, 579, 581, 584, 589
female sexual interest/arousal disorder as, 572, 575–6, 584–5, 590–2
fetishistic disorder as, 598, 602, 603, 605, 613
frotteuristic disorder as, 598–9, 604, 605
gender dysphoria comorbidity with, 602, 604, 635
 genetic risk factors for, 583, 584, 585
genital-pelvic pain-penetration disorder as, 571, 572, 576, 585–6, 592–3, 595–6
hypersexual disorder as, 11
learning and modeling of, 610–11
male hypoactive sexual desire disorder as, 572, 573, 574, 576–7, 581, 586, 587, 593–4, 595
masturbation in, 583, 584, 587, 589, 594, 597, 610, 612
mindfulness approaches for, 589, 592, 593
neurobiological function in, 609–10, 651
other specified sexual dysfunctions/ paraphilias as, 572, 577, 603
pedophilic disorder as, 599–600, 603, 604, 605, 609–10, 611, 651
phallometric testing for, 586, 593
physical illness comorbidity with, 68, 573, 577, 579, 582, 583–4
physiotherapy for, 586, 593
polygraph testing for, 608–9
premature (early) ejaculation as, 572, 577, 579, 581, 586–7, 594–5
psychoeducation for, 591, 596
psychological and biological assessments of, 582–3, 606–9
racial, ethnic and cultural factors in, 573, 579, 581, 583, 585, 688, 601
relaxation training for, 589, 596
sexual abuse (see Physical and sexual abuse) sexual addictions as, 11
sexual masochism disorder as, 583, 600–1, 603–4, 605–6, 613
sexual obsessions, 361
sexual pain disorder as, 572, 576
sleep disorders including sexual behaviors, 555, 560, 561, 562
substance/medication induced sexual dysfunction as, 572, 577
transvestic disorder as, 602, 603, 604, 640, 643, 649, 653–4, 655
treatments and interventions for, 578, 587–95, 611
unsafe sex practices, 67
unspecified sexual dysfunctions/ paraphilias as, 572, 577, 603
vaginismus as, 576, 592, 593
vestibulectomy for, 593
voyeuristic disorder as, 602–3, 604, 606, 612
Sexual masochism disorder, 583, 600–1, 603–4, 605–6, 613
Sexual orientation, gender dysphoria and, 637–9, 643, 651, 652, 654, 656
Sexual sadism disorder, 601–2, 606–7, 611
Shenjing shuairuo, as culturebound syndrome, 138–9
Shopping addiction, 11
Sleep and sleep disorders: actigraphy in, 551–2, 553, 555, 557
age influences and differences in, 550, 554, 558, 560, 561
anxiety comorbidity with, 549, 552, 553, 554, 558, 559, 564
bipolar disorder comorbidity with, 557
breathing-related sleep disorders as, 549, 553, 562
case study of, 563–4
circadian rhythm sleep-wake disorders as, 549, 552, 553, 556–8

---

Subject Index

---

876
depression comorbidity with, 551, 554, 555–6, 557, 561, 562
diagnostic considerations for, 553–4, 555, 557, 559, 560, 562
dissociative disorder comorbidity with, 460, 468, 476–7
epidemiology of, 549, 552–3, 554–5, 556, 558, 560, 561
etiological considerations for, 553, 555, 556–7, 558–9, 560, 561–2
gender influences and differences in, 553, 560
genetic risk factors for, 550, 555, 556, 558
healthy sleep, 550–2
hypersomnolence disorder as, 549, 554–6, 557
inadequate/excessive sleep, 554–6, 564
insomnia disorder as, 549, 552–4, 557, 559, 562, 563, 564
life functioning with, 554, 556
Multiple Sleep Latency Test (MSLT), 552
narcolepsy as, 549, 552, 554, 555, 561
neuroscience/neurobiological function in, 550, 558, 560
nightmare disorder as, 549, 552, 554, 555, 561
non-rapid eye movement (NREM) sleep arousal disorder as, 549, 561–2
obesity comorbidity with, 553, 554
overview of, 549
parasomnias as, 559, 560, 562
pharmacologic interventions for, 478, 565
polysomnography in, 551, 552, 555, 557, 559, 560, 562
psychological and biological assessments of, 549, 551, 555, 565
racial, ethnic and cultural factors in, 554
rapid eye movement (REM) sleep behavior disorder as, 549, 559–61
restless legs syndrome as, 549, 553–4
self-report measures, 551
sleep architecture, 551
sleep measurement, 551
sleep panic attacks as, 562
sleep paralysis as, 559
sleep stages, 550
sleep terrors as, 559, 561, 562
sleep walking as, 560, 561–2
substance/medication induced sleep disorder as, 549
trauma- and stress-related disorders comorbidity with, 410, 553, 555, 558, 559, 563–4
treatments and interventions for, 478–80, 549, 552, 554–5
Sleep terrors, 559, 561, 562
Sleep walking, 560, 561–2
Smoking addiction. See Nicotine use disorders
Social anxiety disorder/social phobia. See also Anxiety disorders
avoidant personality disorder overlap with, 303
behavioral considerations for, 323–4
biological/neurobiological function with, 318–21
bipolar disorder comorbidity with, 223
cognitive-behavioral therapy for, 314, 315–16
cognitive functioning with, 324–7
depression comorbidity with, 308
description of, 303
dual diagnosis including, 53, 56, 59
epidemiology of, 307
etiological considerations for, 318–20
genetic risk factors for, 318, 321
obsessive-compulsive comorbidity with, 364
personality and temperament in, 322
pharmacologic interventions for, 312–13, 316–17
racial, ethnic and cultural factors in, 303
selective mutism in, 303
self-monitoring of, 311
self-report measures for, 310
structured and semistructured interviews on, 115, 309–10
substance use comorbidity with, 53, 56, 59, 308
treatments and interventions for, 312–17
Social functioning:
depressive disorders impacting, 255
feeding and eating disorders impacting, 520, 523
personality disorders impacting, 766, 767 (see also Antisocial personality disorders)
role-play assessment of, 171
schizophrenia impacting, 160, 170–2, 178, 183
social anxiety impacting (see Social anxiety disorder/social phobia)
social skills training for, 178
substance use disorders impacting, 696
Social skills training, 178
Society for Adolescent Medicine, 523
Sociocultural factors. See also
- Racial, ethnic and cultural factors
- Age cohort as, 136–137 in dissociative disorders, 471–80
- For ethnic minorities, 132, 135–7 in dissociative disorders, 471–80
- In feeding and eating disorders, 506
- In neurocognitive disorders, 740
- Socioeconomic status as, 75, 132, 135–136, 169, 601, 740
- Stressful life events as, 136 (see also Environmental risk factors)
- In substance use disorders: alcohol, 671, 681, 684

Socioeconomic status:
- Common factors model on, 75
- Dual diagnosis relationship to, 75
- Of ethnic minorities, 132, 135–136
- Neurocognitive disorders association with lower, 740
- Paraphilic disorders associated with higher, 601
- Schizophrenia association with lower, 169

Somatic symptom and related disorders:
- Anxiety disorder comorbidity with, 440, 443
- Case study of, 441–3
- Clinical picture of, 430–3
cognitive-behavioral therapy for, 440
cognitive functioning with, 439
conversion disorder as, 429, 431–2, 434, 436, 438
Costs of, 430, 436, 441
Course and prognosis of, 440–1
depressive disorder comorbidity with, 254, 256, 435, 442
description of, 429–30
diagnostic considerations for, 433–4
dimensional vs. categorical classification of, 8
dual diagnosis including, 433–4
environmental risk factors for, 438–9
epidemiology of, 435–6
etiological considerations for, 438–40
factitious disorder as, 429, 432–3
fibromyalgia as, 438
gender influences and differences in, 439–40
genetic risk factors for, 438 hypochondriasis as, 6, 434, 435, 438, 439, 440
illness anxiety disorder as, 429, 430, 431, 433, 434, 435–6
learning and modeling of, 438–9
life functioning with, 437, 438–9
neurasthenia similarity to, 139
neuroanatomy in, 438
neurobiological function in, 438
Other specified, 429, 433
pain disorder as, 431, 435, 438
Personality disorder comorbidity with, 435, 440
Pseudocyesis as, 433, 434
Psychological and biological assessments of, 435–6, 436–7
Psychological factors affecting other medical conditions as, 432
Racial, ethnic and cultural factors in, 139, 140, 439–40
Somatic symptom disorder as, 429, 430–1, 433, 434, 435, 437, 440–1
Structured and semistructured interviews on, 115, 435–6, 436–7
Treatments and interventions for, 440–1
Unspecified, 429, 433, 436
Somatic Symptom Workgroup, 433
Spiegel, Herbert, 473
Spirituality and religion:
- As racial, ethnic and cultural factors, 141, 180
- Religious obsessions, 361, 371
- Schizophrenia and, 180
Spitzer, Robert, 21
Stanley Foundation Network study, 213
Stigmatization:
- Dual diagnosis impacted by changes in, 52, 67
- Of neurocognitive disorders, 726, 731
- Of nicotine use disorder, 52, 67
- Of personality disorders, 14–15, 16
- Racial, ethnic and cultural factors in, 140–1, 145, 181
- Of schizophrenia, 179, 181
- Of somatic symptom and related disorders, 433, 434
Stress-related disorders. See
- Trauma- and stress-related disorders
Structured and semistructured interviews:
- Advantages and disadvantages of, 108–12
- Age influences on, 111
Anxiety and Related Disorders interview Schedule for DSM-5
(ADIS-5), 114–16
- For anxiety disorders, 110, 114–16, 118, 120, 309–10
Anxiety Disorders Interview Schedule for
DSM-5, 112, 114–16, 309, 414
ADIS-5L, 116, 366
applications of, 107–12
basic issues regarding, 106–7
for bipolar disorder, 224
breadth vs. depth trade-off with, 108, 111–12
classification system limitations on, 108, 111
for clinical disorders, generally, 105
clinical practice use of, 107
clinical training use of, 107, 110
Cultural Formulation interview, 126–7
for depressive disorders, 111, 115, 118, 119, 121, 124, 265, 265, 267–8
Diagnostic Interview for DSM-5 Personality Disorders, 112, 121–2
Diagnostic Interview Schedule for DSM-5, 112, 116–18
for differential diagnosis, 105–17
for dissociative disorders, 461–2
for dual diagnosis, 46, 56, 57, 72
for feeding and eating disorders, 502–3
international Personality Disorder Examination, 112, 114, 122–3
for obsessive-compulsive anxiety disorders, 120, 366–7
for personality disorders, 105, 106–7, 111, 112, 118, 121–6, 127, 772
for psychoses or psychotic disorders, 118–19
rapport hindrance through, 108, 110–11
reliability of, 106, 108–9, 127
research-based use of, 107, 109, 121
Schedule for Affective Disorders and Schizophrenia, 112, 113, 118–19
for schizophrenia, 111, 112, 118–19, 164, 168, 170–2
for somatic symptom and related disorders, 115, 435–6, 436–7
Structured Clinical Interview for DSM-5 Disorders, 119–21, 309, 437
Structured Clinical Interview for DSM-5 Disorders–Clinician Version (SCID-5-CV), 366, 385
Structured Clinical Interview for DSM-IV, 224, 267, 414, 437, 461, 502
Structured Clinical Interview for DSM-IV Axis I Disorders, 224
Structured Clinical Interview for DSM-IV Axis II Personality Disorders, 123–4
Structured Clinical Interview for DSM-IV-Revised (SCID-D-R), 461
Structured Clinical Interview for DSM-IV-TR Axis II Personality Disorders (SCID-II), 772
Structured Interview for Anorexic and Bulimic Disorders (SIAB-EX), 502, 503
Structured Interview for DSM-5 Personality, 112, 124–6
Structured Interview of Personality Organization, 773
for substance use disorders, 114, 115, 118, 120, 700–2
for trauma- and stress-related disorders, 414
unstructured vs., 105, 109, 112
validity of, 107, 108, 109, 111–12, 121, 123, 126, 127
Substance-related and addictive disorders: alcohol
age influences and differences in, 674
alcoholic Korsakoff’s syndrome, 737, 747, 749
anxiety disorder comorbidity with, 673, 678
barriers to change in, 679
biochemical measures 679–80
biological assessments, 675–80
bipolar disorder comorbidity with, 223
case study of, 685–7
classical conditioning of, 682
clinical picture of, 671–2
cognitive functioning with, 62–3, 678, 681, 683, 686
course and prognosis of, 685
depressive disorders comorbidity with, 257–8, 673, 678, 684–5
description of, 669–71
diagnosis and assessment impacted by, 70–2
diagnostic considerations for, 672–4
dimensional vs. categorical classification of, 10–14, 47–8
dual diagnosis including, 46, 47, 48–50, 52, 54, 55–7, 58, 59–62, 63, 64–6, 68, 70, 71–2, 73, 75–6, 79, 81–2
environmental risk factors for, 415, 682–4
epidemiology of, 674–5
etiological considerations for, 681–5, 746–7
Substance-related and addictive disorders:
- alcohol (Continued)
  - gender influences and differences in, 674, 681, 682, 684, 685, 687
  - learning and modeling of, 682–3
  - motivational interventions for, 672, 676, 679, 686, 687–8
  - neurobiological function in, 681–2, 746
  - neurocognitive disorders and, 737–8, 739, 746–7, 749–50
  - operant conditioning of, 682
  - other substance use comorbidity with, 673
  - personality disorder comorbidity with, 673, 778
  - physical illnesses associated with, 67–8, 680
  - psychological assessments of, 675–80
  - psychopathology research impacted by, 72–4
  - racial, ethnic and cultural factors in, 134, 148, 674, 684–5
  - secondary psychiatric disorder models on, 80–1
  - secondary substance abuse models on, 77
  - self-monitoring of, 676–7
  - service utilization impacted by, 65–7
  - severity rating of, 669, 670, 671, 673–4, 675, 676, 677, 684, 685, 687
  - suicide/suicide ideation association with, 65
  - trauma- and stress-related disorder comorbidity with, 413, 683
  - treatments and interventions for, 669, 672, 673, 675, 676–7, 685, 686
  - treatments and interventions impacted by, 63–5, 65–6, 68
  - violence associated with, 63–5, 674
  - withdrawal symptoms with, 670, 673–4
  - Substance-related and addictive disorders: drugs:
    - age influences and differences in, 53–4, 695, 696, 704
    - anxiety disorder comorbidity with, 50–9, 63, 66, 69, 70, 71, 82, 83, 305, 308, 698, 699, 709
    - assessment 699–704
    - behavioral genetics, 704
    - bidirectional models on, 82
    - biological detection, 703–4
    - bipolar disorder comorbidity with, 52, 54, 62, 67, 71, 73, 78, 79, 223
    - brain reward circuits, 707
    - brain stress circuits, 707–8
    - cannabinoids in, 697, 699
    - case study of, 712–13
    - central nervous system depressants in, 697
    - classical conditioning of, 682
    - clinical impacts of, 59–71
    - clinical picture of, 696–9
    - clinical studies of, 45, 55–9
    - cognitive functioning with, 61–3, 706–9
    - common factors models on, 75–6
    - comorbidity 698–9
    - costs of, 65, 695, 699
    - course and prognosis of, 711–12
    - depressive disorder comorbidity with, 46, 48, 50, 52, 54, 55–7, 58–61, 65, 66, 69, 70, 72, 75, 77, 79, 80–1, 247, 257–9, 673, 678, 684–5, 698, 713
    - diagnosis and assessment impacted by, 70–2, 72–4
    - diagnostic considerations for, 695–6
    - dimensional vs. categorical classification of, 5, 10–14, 21, 47–8
    - dissociative anesthetics in, 698
    - dissociative disorder comorbidity with, 460
    - drug-specific, 148, 223, 257–8, 695, 697, 698, 748
    - dual diagnosis including, 46–84
    - environmental risk factors for, 415, 705, 706, 712
    - epidemiological studies of, 46, 48–55, 698, 708
    - etiological considerations for, 704–10, 746–7
    - executive functioning, 706–7
    - feeding and eating disorder comorbidity with, 56, 57, 500, 709
    - functioning impacted by, 59–63, 64, 70, 71, 75–6, 77, 79, 81, 696, 702, 706–7, 747
    - gambling disorder relationship to, 11, 47–8, 51, 120
    - gender dysphoria comorbidity with, 641
    - gender influences and differences in, 46, 68–9, 709
    - gene-environment interactions, 705
    - genetic risk factors for, 75–6, 704–5, 746–7, 749–50
    - hallucinogens in, 695, 697, 698
    - homelessness associated with, 68
    - inhalants in, 698
    - learning and modeling of, 705–6
    - legal problems or criminality as factor in, 60, 68
life functioning with, 60–1, 702, 706–7
mental disorder
comorbidity with, 45–84, 163, 165–6, 223, 247, 257–8, 305, 308, 364, 413, 460, 500, 641, 698–9, 706–7, 778
methodological issues in assessment of, 45–8
molecular genetics, 704–5
neuroadaptation in reward and stress circuitry, 708–9
neuroanatomy and neurobiology, 707–9
neurobiological function in, 706, 707–9, 746
neurocognitive disorders and, 727, 733, 737, 739, 746–50
nicotine-specific, 47, 52, 57, 79–80, 704, 739
obsessive-compulsive disorder comorbidity with, 46, 56, 59, 364
operant conditioning of, 682
opioids in, 697
personality disorder
comorbidity with, 54, 62, 67, 73–4, 78, 79, 698–9, 778
physical illnesses impacted by, 67–8
physiological and psychological effects 697–8
prescription drugs in, 697, 711
psychological and biological assessments of, 699–704
psychopathology research impacted by, 72–4, 83
racial, ethnic and cultural factors in, 134, 148–9, 709–10
schizophrenia comorbidity with, 46, 54, 62, 67, 73–4, 78, 79, 162, 165–6, 187, 698
screening, 699–702
secondary psychiatric disorder models on, 80–2
secondary substance abuse models on, 76–80
self-medication through, 76–80
severity rating of, 696, 713
sexual orientation, 710
social functioning with, 696
stimulants in, 697–8
structured and semistructured interviews on, 114, 115, 118, 120, 700–2
substance-induced depressive disorder, 70–2, 248, 250–1, 258
substance-induced neurocognitive disorder, 727, 733, 739
substance-induced psychoses, 699
substance-induced sexual dysfunction, 572, 577
substance-induced sleep disorder, 549
suicide/suicide ideation association with, 53, 61, 64–5, 68
symptom overlap with, 166–7
theories on dual diagnosis including, 74–82
trauma- and stress-related disorder comorbidity with, 46, 56–7, 59, 60–1, 64, 65, 67–8, 70, 77–8, 413
treatments and interventions for, 669, 670, 699–702
treatments and interventions impacted by, 63–5, 65–6, 68
violence associated with, 63–5
withdrawal symptoms with, 696, 697–8
Suicide and suicide ideation: bipolar disorder comorbidity with, 65, 212, 214, 227
body dysmorphic disorder comorbidity with, 362, 382, 386
depressive disorder comorbidity with, 65, 247
dissociative disorder comorbidity with, 460, 479
dual diagnosis impacting, 64–5
gender dysphoria comorbidity with, 641, 647, 649
obsessive-compulsive disorder comorbidity with, 362, 382, 385
personality disorder comorbidity with, 757
schizophrenia comorbidity with, 65, 161, 166
substance use comorbidity with: alcohol, 53, 61, 64–5, 68
substance use comorbidity with: drugs, 53, 61, 64–5, 68
trauma- and stress-related disorders comorbidity with, 65, 412, 413
Susto, as culture-bound syndrome, 137–8
Sybil (Sybil book/movie), 461, 473
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 212, 220, 230
Taijin Kyofusho, as culturally bound syndrome, 303, 329
Tay-Sachs disease, 748, 750
Temperament. See Personality and temperament
Theories: bidirectional models as, 82
common factors models as, 75–6
of dual diagnosis, 74–82
item response theory (IRT) methodology, 12–13
localization theory, 728–9, 740
Theories (Continued)
  preparedness theory, 324
  secondary psychiatric disorder models as, 80–2
  secondary substance abuse models as, 76–80
  Thiamine treatments, 747
  Tobacco addiction. See Nicotine use disorders
Training. See Coping skills training; Habit reversal training;
  Psychoeducation;
  Relaxation training;
  Social skills training;
  Stress management training
  Transference-focused therapy, 771
Transsexualism:
  case study of, 655–6
  clinical picture of, 635–9
  cognitive functioning with, 653–4
  course, 645–6
  description of, 633–5
  diagnostic considerations for, 639–42
  environmental risk factors for, 649–50, 653
  epidemiology of, 642–3
  etiological considerations for, 649–54
  gender influences and differences in, 636, 637–9, 640, 641, 642–3, 644, 645, 647–8, 649–50, 651–2, 654
  genetic risk factors for, 649–50
  history and terminology of, 635–5
  hormone therapy for, 640, 642, 645–7, 648, 650–2, 654, 655, 656
  learning and modeling of, 653
  neurobiological function in, 650–3
  psychological and biological assessments of, 643–4
  racial, ethnic and cultural factors in, 654
  sex reassignment for, 633, 635, 637–8, 640, 642, 643, 645–6, 647, 648–9, 655, 656
  treatments and interventions for, 633, 636, 639, 640, 642, 643, 644, 646–9, 655–6
  Transtheoretical model (TTM), 702
Transvestic disorder:
  clinical picture of, 602
  diagnostic considerations for, 603–4
  epidemiology of, 606
  gender dysphoria association with, 602, 604, 640, 642, 643, 644, 646–9, 655
  Trauma- and stress-related disorders:
    acute stress disorder as, 6, 409, 410–11, 412, 413, 414, 416–17, 419–20, 421
    adjustment disorders as, 409, 411, 412–13, 414, 416, 417, 419, 420
    anxiety comorbidity with, 413
    bipolar disorder comorbidity with, 223
    case studies of, 420
    clinical features of, 411–12
    cognitive-behavioral therapy for, 418
    cognitive functioning with, 417
    cognitive restructuring for, 418
    course and prognosis of, 417–19
    depression comorbidity with, 412
    description of, 409–11
    diagnostic considerations for, 412–13
    dimensional vs. categorical classification of, 6
    dissociation, posttraumatic model of, 451, 452, 471–80
    dual diagnosis including, 46, 56–7, 59, 60–1, 64, 65, 67–8, 70, 77–8, 882
    environmental risk factors for, 416–17
    epidemiology of, 413
    etiological considerations for, 414–17
    exposure therapy for, 417, 418
    feeding and eating disorder comorbidity with, 517, 526
    gender influences and differences in, 417
    genetic risk factors for, 414–15
    learning and modeling of, 416–17
    neurobiological function in, 415–16
    neurocognitive disorder comorbidity with, 725, 743
    personality and temperament in, 322
    personality disorder comorbidity with, 57, 413
    pharmacologic interventions for, 419
    physical illnesses associated with, 67
    psychoeducation for, 418
    psychological and biological assessments of, 414, 461–2
    psychological debriefing interventions for, 419
    racial, ethnic and cultural factors in, 131, 137–8, 142, 417
    relaxation training for, 419
    schizophrenia comorbidity with, 163–4, 177
sleep disorder comorbidity with, 410, 558–9, 563–4
structured and semistructured interviews on, 414
substance use comorbidity with: alcohol, 46, 56–7, 59, 60–1, 64, 65, 67–8, 70, 77–8, 413, 683
substance use comorbidity with: drug, 46, 56–7, 59, 60–1, 64, 65, 67–8, 70, 77–8, 413
suicide/suicide ideation comorbidity with, 65, 412, 413
symptom overlap with, 70, 413, 421
treatments and interventions for, 417–19
Traumatic brain injury, 725–6, 727, 732, 733, 742, 743–4
Treatments and interventions:
  acceptance and commitment therapy as, 315, 384
  for anxiety disorders, 312–17
  behavioral family therapy as, 181
  for bipolar disorder, 65, 212, 217–20, 227
  clinician and client interplay in, 143–4
cognitive-behavioral therapy as, 218, 219, 313–14, 382–4, 418–19, 467, 478, 440, 524, 589, 591, 593, 611, 613
cognitive restructuring as, 314, 382, 418, 467
coping skills training as, 177
for depressive disorders, 10, 247, 255, 278
diagnosis as foundation for, 127, 675
dialectical behavior therapy as, 384, 467, 771
for dissociative disorders, 467, 478–80
dual diagnosis impacting,
  63–5, 65–6, 68
EROS Clitoral Therapy Device as, 589, 592
exposure therapy as, 314, 317, 418
eye movement desensitization and reprocessing as, 315
family-focused therapy as, 219, 220, 523
for feeding and eating disorders, 517, 522–4
for gender dysphoria, 633, 636, 639, 640, 642, 644, 645–9, 655, 656
Guided Self-Change as, 686
habit reversal training as, 379, 384
hormone therapy as, 640, 642, 645–7, 648, 650–2, 654, 655, 656
insurance coverage for, 14
interpersonal and social rhythm therapy as, 218–20
interpersonal therapy as, 315, 523, 524
meditation as, 315
mentalization-based therapy as, 771
mindfulness approaches to, 315, 467, 589, 592, 593
motivational interventions as, 672, 676, 679, 687
for neurocognitive disorders, 747, 751
noncompliance with, 63–5, 148, 162–3, 218, 712
for obsessive-compulsive disorders, 382–4
for personality disorders, 70, 757, 771, 778
pharmacologic (see Pharmacologic interventions)
physiotherapy as, 586, 593
positive psychology as, 255
psychoanalytic psychotherapy as, 315
psychoeducation as, 218, 314, 383, 385, 387–9, 591, 596
psychological debriefing interventions as, 419
racial, ethnic and cultural factors impacting, 131–2, 134, 135–8, 141, 143–9, 180–1, 212, 709–10
relaxation training as, 314, 419, 467, 589, 596
schema-focused therapy as, 771
for schizophrenia, 65, 162–3, 176
service utilization of, 65–7, 131, 132, 180, 709–10
sex reassignment as, 633, 635–7, 640, 642, 643, 645–6, 647, 648–9, 655, 656
for sexual dysfunctions and paraphilic disorders, 587–95, 596, 611
for sleep disorders, 478–80, 549, 552, 554–5
for somatic symptom and related disorders, 440
substance use impacting, 63–5, 65–6, 68
Systematic Treatment Enhancement Program for Bipolar Disorder as, 212, 220, 230
thiamine treatments as, 747
transference-focused therapy as, 771
for trauma- and stress-related disorders, 417–19
Uniting Couples (in the treatment of) Anorexia Nervosa (UCAN), 523
vacuum construction devices as, 588
vestibulectomy as, 593
Trichotillomania (TTM): case study of, 389
clinical features of, 363
cognitive influences, 379
course and prognosis of, 381
description of, 360
diagnostic considerations for, 364–5, 367
environmental risk factors for, 369, 375–6
Trichotillomania (TTM) (Continued)
epidemiology of, 365–6
etiological considerations for, 369, 370, 373
gender influences and differences in, 381
 genetic risk factors for, 370
 neurobiological function with, 373
 psychological and biological assessments of, 366–8
 racial, ethnic and cultural factors in, 381
structured and semifstructured interviews on, 120
treatments and interventions for, 384
 Trisomy 21, 19, 739, 749
 Tuberous sclerosis, 19
 Turner’s syndrome, 636
 Tuskegee Study of Untreated Syphilis in the African American Male, 147
 Uniting Couples (in the treatment of) Anorexia Nervosa (UCAN), 523
 Urinalyses, 679–80, 703
 Vacuum construction devices (VCD), 588
 Vaginismus, 576, 592, 593
 Validity of diagnosis and assessment, 107, 108, 109, 111–12, 121, 123, 126, 127, 777
 Vascular neurocognitive disorder, 727, 732–3, 744
 Vestibulectomy, 593
 Violence. See also Anger and hostility
dual diagnosis association with, 63–4
 paraphilic disorders involving, 573, 602, 608, 612
 physical and sexual abuse as (see Physical and sexual abuse)
racial, ethnic and cultural factors in, 148
 schizophrenia and, 163, 177, 179
 self- (see Suicide and suicide ideation)
sleep disorders and, 560
 substance use associated with: alcohol, 63–4, 674
 substance use associated with: drugs, 63–4
 trauma disorders associated with (see Trauma- and stressrelated disorders)
 Von Recklinghausen’s disease, 19
 Voyeuristic disorder, 602–3, 604, 606, 612
 Weight issues. See Feeding and eating disorders; Obesity
 Wellcome Trust Case Control Consortium, 508
 Wernicke-Korsakoff syndrome, 747
 Wernicke’s aphasia, 734
 White, William Alanson, 764
 Wilbur, Cornelia, 473
 Women. See also Gender influences and differences
 amenorrhea in, 498
dual diagnosis issues for, 68–9
 female orgasmic disorder in, 572, 574, 575, 579, 581, 584, 589
 female sexual interest/arousal disorder in, 572, 575–6, 584–5, 590–2
 gender dysphoria in, 602, 633–56
 genito-pelvic pain-penetration disorder in, 571, 572, 576, 585–6, 592–3, 595–6
 paraphilic disorders in, 597–8, 600, 601, 602, 604
 physical and sexual abuse of, 69, 179 (see also Physical and sexual abuse)
pregnancy among, 69, 253, 374, 433
 premenstrual syndromes in, 120, 139, 248, 250
 substance use among, specifically: alcohol, 68–9, 674, 684
 substance use among, specifically: drugs, 68–9, 709
 World Health Organization (WHO):
bipolar disorder epidemiological study by, 211
Composite International Diagnostic interview (CIDI), 10, 52, 118, 267, 437, 502
ICD by (see International Classification of Diseases)
Joint Program for the Diagnosis and Classification of Mental Disorders, 122
Mental Health Epidemiologic Survey, 413, 500
normal weight guidelines of, 498
schizophrenia epidemiological study by, 168
substance use: alcohol, epidemiological statistics by, 674
 Well-Being Index (WHO-5), 266–7
World Mental Health Surveys (WMHS), 52
 Yale Family Study of Comorbidity of Substance Disorders, 75